<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Syst Rev</journal-id><journal-id journal-id-type="iso-abbrev">Syst Rev</journal-id><journal-title-group><journal-title>Systematic Reviews</journal-title></journal-title-group><issn pub-type="epub">2046-4053</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40410915</article-id><article-id pub-id-type="pmc">PMC12100989</article-id><article-id pub-id-type="publisher-id">2764</article-id><article-id pub-id-type="doi">10.1186/s13643-025-02764-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>High-intensity interval training and strength conditioning in patients with chronic lymphocytic leukemia: a systematic review</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Cunha</surname><given-names>Pedro M P</given-names></name><address><email>pedrocunha@fade.up.pt</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ribeiro</surname><given-names>Ricardo J</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Pizarro</surname><given-names>Andreia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mota</surname><given-names>Jorge</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ribeiro</surname><given-names>Jose C D</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Faculty of Sports, FADEUP) and Laboratory for Integrative, Research Center in Physical Activity, Health and Leisure (CIAFEL)University of PortoTranslational Research in Population Health (ITR), Porto, Portugal </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043pwc612</institution-id><institution-id institution-id-type="GRID">grid.5808.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1503 7226</institution-id><institution>i3S-Instituto de Investiga&#x000e7;&#x000e3;o E Inova&#x000e7;&#x000e3;o Em Sa&#x000fa;de, </institution><institution>Universidade Do Porto, </institution></institution-wrap>Porto, Portugal </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043pwc612</institution-id><institution-id institution-id-type="GRID">grid.5808.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1503 7226</institution-id><institution>INEB-Instituto de Engenharia Biom&#x000e9;dica, Universidade Do Porto, Rua Alfredo Allen, </institution></institution-wrap>208, 4200-180 Porto, Portugal </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043pwc612</institution-id><institution-id institution-id-type="GRID">grid.5808.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1503 7226</institution-id><institution>CAC ICBAS-CHP&#x02013;Centro Acad&#x000e9;mico Cl&#x000ed;nico Instituto de Ci&#x000ea;ncias Biom&#x000e9;dicas Abel Salazar&#x02013;Centro Hospitalar Universit&#x000e1;rio de Santo Ant&#x000f3;nio, </institution></institution-wrap>Porto, Portugal </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04h8e7606</institution-id><institution-id institution-id-type="GRID">grid.91714.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2226 1031</institution-id><institution>Faculty of Health Sciences (FCS), </institution><institution>Fernando Pessoa Hospital, University Fernando Pessoa (UFP), </institution></institution-wrap>4420-096 Porto, Portugal </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>14</volume><elocation-id>116</elocation-id><history><date date-type="received"><day>20</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>8</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">This systematic review explores the impact of physical exercise on chronic lymphocytic leukemia (CLL) patients&#x02019; physical fitness, immunologic, and quality of life outcomes.</p></sec><sec><title>Methods</title><p id="Par2">Eligible studies were searched in PubMed and Web of Science up to February 2024 and were included if they involved participants in adult age, with confirmed CLL diagnose, using physical activity protocols with study design helding intervention protocols, clinical trials, or quantitative data reporting. Bias was assessed with ROBINS-I and RoB2 tools from Cochrane. The results are presented in tables and figures. A qualitative synthesis describes the main outcomes of the included studies. Meta-analysis was not performed due to significant heterogeneity.</p></sec><sec><title>Results</title><p id="Par3">This review identifies 92 studies, with 6 meeting the inclusion criteria, with a sample size of 323 patients. These studies focus on cardiovascular training combined with resistance training (four studies with total sample of 177 patients), continuous cardiovascular training (one study with 122 patients), and endurance resistance training (one study with 24 patients), highlighting the importance of physical exercise in CLL patients before treatment, with significant improvements in physical fitness and immunologic parameters on intervention groups.</p></sec><sec><title>Discussion</title><p id="Par4">The paucity regarding exercise influence on CLL, with small samples of patients in pilot study experiments, noted that exercise plays a vital role in improving physical fitness and immunologic parameters. However, none addressed strength training, which is known as one of the best options to increase muscular mass in physical activity interventions. The inconsistency of intervention and/or evaluation protocols ravels the advice of exercise and medical professionals on prescribing different modes of exercise, improving compliance with the prescribed exercise program, and determining which intervention in the context of exercise prescription should be used. More studies are needed to evaluate the impact of physical activity on the health-related quality of life and life span of the CLL patient.</p></sec><sec><title>Trial registration</title><p id="Par5">PROSPERO CRD42023464877.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Physical activity</kwd><kwd>Exercise</kwd><kwd>Resistance training</kwd><kwd>Quality of life</kwd><kwd>Chronic lymphocytic leukemia</kwd><kwd>Oncology</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005856</institution-id><institution>Faculdade de Ci&#x000ea;ncias e Tecnologia, Universidade Nova de Lisboa</institution></institution-wrap></funding-source><award-id>2021.07178.BD: DOI 10.54499/2021.07178.BD</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par6">Chronic lymphocytic leukemia (CLL) is a type of blood cancer described as a neoplasm composed of monomorphic small mature B cells that co-express CD5 and CD23 surface marker antigens [<xref ref-type="bibr" rid="CR1">1</xref>], which leads to a progressive accumulation of monoclonal B lymphocytes [<xref ref-type="bibr" rid="CR2">2</xref>]. In the diagnosis of CLL, CD5, CD19, CD20, CD23, surface or cytoplasmic kappa, and lambda light chains are regarded as essential markers, and CD10, CD43, CD79b, CD81, CD200, and ROR1 as additional targets useful in the differential diagnosis from other small B-cell lymphomas/leukemias [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par7">CLL is the most common chronic leukemia among adults in Western countries, making up 25 to 35% of all leukemia cases in the USA [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. In Europe, leukemia has risen to become the eighth leading cause of cancer-related deaths since 2019, with an increasing tendency [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. With a male preponderance CLL represent 7% of non-Hodgkin lymphomas [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>], most frequently diagnosed between 65 and 74 years old, but individuals 45&#x02013;64 already represent more than 30% of newly diagnosed cases [<xref ref-type="bibr" rid="CR4">4</xref>]. Incidence rates are lower in the Asian and Black ethnic groups, compared with Caucasian due to genetic predisposition, environmental factors, healthcare disparities, or age distribution [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par8">There are CLL-related mortality attributable risk factors that include elevated body mass index, occupational exposure to benzene, formaldehyde and to cigarette smoke [<xref ref-type="bibr" rid="CR5">5</xref>]. However, when analysing data from low Social-Demographic Index areas, high body mass index showed a significant upward trend [<xref ref-type="bibr" rid="CR5">5</xref>]. As the disease progresses, symptoms arise and include fatigue, shortness of breath during regular physical activity, lymph node enlargement, low-grade fever, unexplained weight loss, night sweats, feeling of fullness (related to enlarger spleen or liver) or infection of the skin, lungs, or sinuses [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. These symptoms impair physical fitness performance and daily activities, reducing the health-related quality of life. The diagnostic workup includes microscopic examination, immunophenotyping, fluorescence in situ hybridization (FISH), determination of CD38 and ZAP-70 expression, and the mutational status of IgHV genes in blood and/or bone marrow [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par9">The most promising targeted therapies, including BCL-2 inhibitors and Bruton tyrosine kinase (BTK) inhibitors, are unable to offer a cure for CLL, while representing an economic burdensome with severe adverse events [<xref ref-type="bibr" rid="CR5">5</xref>]. It is during the phase of active surveillance that physical activity may have an important role, putatively delaying symptoms and disease progression.</p><p id="Par10">In chronic lymphocytic leukemia, prognostication has been supported by the Rai and Binet clinical staging systems, which rely on physical examination and standard laboratory tests [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. However, they lack genetic and molecular testing, giving rise to the CLL International Prognostic Index (CLL-IPI) which emerged as a more comprehensive prognostic framework [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>] that combines genetic, biochemical, and clinical parameters into a five-categories prognostic model [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par11">A less favourable prognostic outcome is associated with blood lymphocyte doubling time, complex karyotypes (Del 17q and Del 11q), expression of CD38, CD49d, and ZAP-70, and mutations on <italic>TP53</italic>, <italic>NOTCH1</italic>, and <italic>SF3B1</italic> genes [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par12">The survival of CLL cells strictly depends on a permissive and nurturing microenvironment [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], which produces various proteins (chemokines, cytokines, and angiogenic factors) that interact with leukemic cells via surface receptors or adhesion molecules to support their survival and aggressiveness. On the other hand, the immune response against leukemic cells is compromised due to &#x0201c;exhaustion&#x0201d; of the cytotoxic T cells, and a suppressive immunological synapse formation with antigen-presenting cells [<xref ref-type="bibr" rid="CR18">18</xref>]. Furthermore, natural killer (NK) cells acquire a phenotype that yields reduced ability to lyse CLL cells due to lack of cytoplasmic granules and impaired establishment of immunological synapse [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par13">Intensive endurance exercise is known to induce lymphocyte apoptosis, which may affect immune function [<xref ref-type="bibr" rid="CR19">19</xref>]. Regular resistance exercise decreases oxidative stress by enhancing antioxidant enzyme activity, which may lead to attenuated apoptosis-related proteins, such as caspase-3, BAX and BCL-2 expression [<xref ref-type="bibr" rid="CR20">20</xref>]. Noteworthy, high-intensity interval training (HIIT) studies suggest that it is able to delete mainly differentiated T cells known to affect immunity to control latent infections, in contrast with continuous exercise that impacts survival of undifferentiated T cells, which might affect immunosurveillance and cytotoxic ability [<xref ref-type="bibr" rid="CR21">21</xref>]. In recent years, scientific evidence revealed that skeletal muscle role in human physiology goes beyond the locomotor unit responsible for movement and posture, to include a major part on regulation in energetic and metabolic processes involved in the regulation of glucose and lipid metabolism, immunomodulation, anti-inflammatory, and inhibition of migratory mononuclear cells (such as macrophages and T-cells) towards the inflamed microenvironment (such as adipose tissue of obese persons) [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. Other studies associated exercise-induced myokines production with the ability to increase immune-mediated cytotoxicity and the tumour infiltration by immune cells [<xref ref-type="bibr" rid="CR25">25</xref>], growth and differentiation of muscle tissue promoting hypertrophy, providing energy substrate for contracting muscle fibres, activating mechanisms of energy production during fasting and improving tissue sensitivity to insulin, stimulating thermogenesis, glucose uptake by myocytes, and also contributing to an increase in bone mineral density [<xref ref-type="bibr" rid="CR26">26</xref>]. Literature also demonstrated activation of NK cells after physical exercise [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], with strenuous exercise increasing NK cytotoxicity during exercise, followed by a profound effect with 40% depression of the NK cell count even after cessation of exercise for as long as 7 days [<xref ref-type="bibr" rid="CR29">29</xref>], with maximal exercise of large muscle groups leading to higher immune responses during repetitive bouts and elevated concentrations of leukocytes, neutrophilic granulocytes, and lymphocytes, resulting in leukocyte concentrations and the NK cell activity enhanced not only during exercise bouts, but also on the day after exercise [<xref ref-type="bibr" rid="CR30">30</xref>]. A recent meta-analysis disclosed NK cell activity is largely elevated by acute physical exercise, with more significant effects in endurance versus resistance exercise and increasing with exercise intensity, providing solid evidence that elevated NK cell activity associated with exercise returns to baseline during the first 1&#x02013;2 h of recovery, but not below the pre-exercise values, a proof that the functional change in NK cell activity exists independently from the quantitative change in NK cell count [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par14">To address this complex landscape, many authors advocate for clarification of the effects of exercise on CLL, through the exploration of various exercise paradigms, including type, duration, and intensity, using state-of-the-art methods to detect immunological changes [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. In this review, we endeavour to review and comprehensively describe existing physical activity protocols for CLL patients and analyse their effects. Additionally, we aim to identify potential gaps in best practices related to the evaluation of physical activity, lifestyle patterns, and immunologic outcomes. Our findings will not only guide future research but also pave the way for innovative interventions in this crucial area.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par15">This systematic review was elaborated based on the methods outlined in the Cochrane handbook [<xref ref-type="bibr" rid="CR34">34</xref>], and we also adhere to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines [<xref ref-type="bibr" rid="CR35">35</xref>] reporting standards. The purpose of this systematic review was to identify the relationship between physical activity (particularly HIIT and resistance training) and chronic lymphocytic leukemia, regarding fitness, health-related quality of life and feasibility, and immunologic parameters.</p><sec id="Sec3"><title>Literature search strategy</title><p id="Par16">This study was registered at PROSPERO database (CRD42023464877). Afterwards, automated searches were made in the PubMed and Web of Science databases up to February 2024, with no restriction on the initial date period. Free text terms were searched using the Boolean operators AND/OR applied to the title or abstract:<list list-type="bullet"><list-item><p id="Par17"><bold>PubMed search key:</bold> ((physical exercise) OR (aerobic training) OR (strength training) OR (exercise) OR (motor activity) OR (physical fitness) OR (physical activity) OR (intensive strength training) OR (resistance training) OR (plyometric exercise) OR (exhaustive exercise) OR (physical endurance) OR (exercise tolerance) OR (aerobic fitness) OR (strength endurance training) OR (strengthening exercise) OR (HIIT) OR (high intensity exercise) OR (high intensity interval training)) AND ((CLL) OR (Chronic lymphocytic leukemia) OR (leukemia)).</p></list-item><list-item><p id="Par18"><bold>Web-of-Science search key:</bold> TS&#x02009;=&#x02009;((physical exercise) OR (aerobic training) OR (strength training) OR (exercise) OR (motor activity) OR (physical fitness) OR (physical activity) OR (intensive strength training) OR (resistance training) OR (plyometric exercise) OR (exhaustive exercise) OR (physical endurance) OR (exercise tolerance) OR (aerobic fitness) OR (strength endurance training) OR (strengthening exercise) OR (HIIT) OR (high intensity exercise) OR (high intensity interval training)) AND TS&#x02009;=&#x02009;((CLL) OR (Chronic lymphocytic leukemia) OR (leukemia)).</p></list-item></list></p><p id="Par19">In the case of Web-of-Science, we opted for field tag topic (TS) because it searches for topic terms in the title, abstract, and author keywords, making the search broader.</p><p id="Par20">Articles were systematically screened (from September 2023 to February 2024), resulting in 92 hits after duplicates removal.</p><p id="Par21">The eligibility criteria for this review included any study investigating exercise-based interventions in adult patients with chronic lymphocytic leukemia, following criteria according to population, intervention, comparison, outcomes and study design (PICOS) guidelines: Participants must be in adult age, with confirmed CLL diagnose; intervention must be with physical activity protocols; comparison between control group, or between different physical activity approaches; outcomes are the attributable risk in cancer or molecules numbers progression, overall quality of life and feasibility, or changes in morphologic, biologic, immunologic or physiologic characteristics; study design must held intervention protocols, clinical trials, or quantitative data reporting.</p><p id="Par22">There were no restrictions regarding study design, with both clinical trials (randomized or non-randomized) and cohort studies being included. The focus was on studies evaluating the effects of exercise on clinical or functional outcomes in this population.</p><p id="Par23">Articles must be written in English and available in full text. Gray literature was not included, but a systematic screening of selected papers bibliography was conducted to search for other articles that could be absent on our search. For this review we focused only on chronic lymphocytic leukemia. Variants, such as acute lymphocytic leukemia, myeloid leukemias, and lymphomas, were not considered due to differences in affected cells. No other inclusion or exclusion criteria were applied.</p></sec></sec><sec id="Sec4"><title>Selection process</title><p id="Par24">Two authors independently screened the retrieved records. Due to scarce literature retrieved, and the agreement in the manuscripts to include, there was no need for 3rd investigator for arbitrage. Automated removal of duplicates was performed using EndNote&#x02122; 20.3 for Mac (Clarivate&#x02122;) but further manual removal was also used.</p></sec><sec id="Sec5"><title>Data extraction and methodological study quality assessment</title><p id="Par25">The main characteristics of participants (age, gender, CLL staging described as Rai or CLL-IPI staging) and main study outcomes (quality of life, feasibility, exercise and biologic/physiologic outcomes variables), as well as their interaction, were identified and appraised.</p><p id="Par26">Differences between baseline and post-protocol evaluation are described as mean&#x02009;&#x000b1;&#x02009;standard deviation, in some cases mean (range), or as % of change compared to baseline (with mean&#x02009;&#x000b1;&#x02009;SD also). On our tables, we opted to highlight the non-statistical differences between control and interventions groups, to enlighten the path for future investigations to fulfil the gaps of current knowledge.</p><p id="Par27">The scientific quality of the included randomized clinical trials and observational studies was assessed independently by two reviewers using respectively CONSORT [<xref ref-type="bibr" rid="CR36">36</xref>] and STROBE [<xref ref-type="bibr" rid="CR37">37</xref>] checklist, as they are designed to ensure comprehensive reporting of observational research. Although CONSORT and STROBE are reporting guidelines, we used it as a proxy for assessing the completeness and transparency of reporting studies. In cases of discrepancies, a consensus-based final score was attributed after discussion. It was attributed a score of 0 (if do not meet the criterion) or 1 (if meets the criterion) for every item of the CONSORT and STROBE checklist. The global score was then converted into a percentage qualifying into 3 categories: A, study meets more than 80% of the criteria; B, study meets 50&#x02013;80% of the criteria; and C, study meets less than 50% of the criteria [<xref ref-type="bibr" rid="CR38">38</xref>].</p><p id="Par28">Additionally, the risk of BIAS was assessed based on study type. For non-randomized cohort studies, the risk of bias in non-randomized studies of interventions (ROBINS-I) tool was applied [<xref ref-type="bibr" rid="CR39">39</xref>], which evaluates bias across seven domains, including confounding, selection bias, and outcome measurement. For randomized trials, the Risk of Bias 2 (RoB 2) tool was used [<xref ref-type="bibr" rid="CR40">40</xref>], which focuses on potential biases related to the randomization process, deviations from intended interventions, missing data, outcome measurement, and selection of reported results.</p></sec><sec id="Sec6"><title>Results</title><p id="Par29">For this systematic review, a total of 1853 studies were identified within the search criteria. However, after screening titles and abstracts and applying inclusion/exclusion criteria (adult age patients, CLL malignancy, physical activity intervention protocols, after duplicates removal and excluding review articles) only 6 relevant articles were retrieved for full-text appraisal. Literature also shows associations of exercise in paediatric ages, but as the response to exercise is different in adults, those studies were disregarded while screening titles. One other study [<xref ref-type="bibr" rid="CR41">41</xref>] was not included because it addressed a study-case with an unstructured exercise intervention protocol, without the assessment of initial and end physical fitness outcomes. Among the selected studies, 3 studies were randomised clinical trials (RCT&#x02019;s) with physical activity (PA) intervention and without any prior treatment to CLL disease; 2 studies were pilot studies with CLL patients, and 1 interventional study with physical activity intervention but with previous or ongoing CLL treatment.</p><p id="Par30">In the studies included, physical activity with different types and intensities (aerobic, strength, resistance and HIIT) were objectively assessed. Because CLL exercise intervention remains an unclear field of expertise, literature addressing PA influence in CLL patients (exclusively) disease parameters is rare (only one interventional study and two small Pilot Studies with 24 patients [<xref ref-type="bibr" rid="CR32">32</xref>], 16 patients [<xref ref-type="bibr" rid="CR33">33</xref>], and 15 patients [<xref ref-type="bibr" rid="CR42">42</xref>]), reason that led us to select for inclusion any exercise intervention study that included CLL adult patients in the sample [<xref ref-type="bibr" rid="CR43">43</xref>&#x02013;<xref ref-type="bibr" rid="CR45">45</xref>]. Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> schematize the search flow diagram.<fig id="Fig1"><label>Fig. 1</label><caption><p>PRISMA flow diagram</p></caption><graphic xlink:href="13643_2025_2764_Fig1_HTML" id="MO1"/></fig></p><p id="Par31">Table <xref rid="Tab1" ref-type="table">1</xref> summarizes the quality assessment of each study, according to CONSORT [<xref ref-type="bibr" rid="CR36">36</xref>] and STROBE [<xref ref-type="bibr" rid="CR37">37</xref>] guidelines (as they are designed to ensure comprehensive reporting of observational research, they were used as a proxy for assessing the completeness and transparency of reporting studies); the risk of BIAS was accessed with ROBINS-I tool for non-randomized interventions [<xref ref-type="bibr" rid="CR39">39</xref>], and the RoB 2 tool for randomized controlled trials [<xref ref-type="bibr" rid="CR40">40</xref>]. Although study quality of the selected studies were graded A or B, the authors did not include an estimation of BIAS direction and magnitude, for example, regarding differences in the medical surveillance of participants, physical activity surveillance, follow up of daily activities, and only focused on details about additional data they collected to tackle this problem. The most impactful domains in non-randomized studies for overall risk of BIAS were BIAS due to confounding, while in randomized studies were BIAS due to randomization process and in measurement of outcomes. One study from Crane et al. [<xref ref-type="bibr" rid="CR32">32</xref>] revealed not only Serious risk of BIAS on controlling confounding, but also in classification of intervention, deviation from intended interventions, missing data, and selection of reported result. Knowing the limitations of a home-based approach, it is not clear how the research team controlled the implementation of exercise protocol between groups, and even the BIAS of the selected outcomes (6 min walk test, timed up-and-go, chair stand test, and FACT questionnaires) could be critically contaminated upon measuring; and without a control group to compare to. For primary outcome VO2 assessment, most of the studies have used standardized protocols or gold standard physical evaluation equipment&#x02019;s to reduce BIAS, but regarding muscular evaluation, only Person et al. [<xref ref-type="bibr" rid="CR45">45</xref>] have attempted that BIAS reduction. In all remaining studies were used evaluation tests subjected to major risk of BIAS, mainly due to missing measurement of outcome BIAS control. By using non gold standard physical evaluation while applying questionnaires (inherently subjective) to evaluate secondary outcomes like leisure time activity, physical and functional well-being, the risk of BIAS is greatly augmented.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Study quality according to CONSORT [<xref ref-type="bibr" rid="CR36">36</xref>] and STROBE [<xref ref-type="bibr" rid="CR37">37</xref>] guidelines, and risk of bias according to ROBINS-I tool [<xref ref-type="bibr" rid="CR39">39</xref>] for non-randomized interventions and RoB 2 [<xref ref-type="bibr" rid="CR40">40</xref>] for randomized clinical trials. HL Hodgkin&#x02019;s <italic>l</italic>ymphoma<italic>,</italic> NHL <italic>non-</italic>Hodgkin&#x02019;s <italic>l</italic>ymphoma</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left"/><td align="left"/><td align="left"><bold>STROBE</bold></td><td align="left" colspan="8"><bold>ROBINS-I</bold></td></tr><tr><td align="left"><bold>Study</bold></td><td align="left"><bold>Pathology</bold></td><td align="left"><bold>Study quality</bold></td><td align="left"><bold>BIAS due to confounding</bold></td><td align="left"><bold>BIAS in selection of participants</bold></td><td align="left"><bold>BIAS in classification of interventions</bold></td><td align="left"><bold>BIAS due to deviations from intended interventions</bold></td><td align="left"><bold>BIAS due to missing data</bold></td><td align="left"><bold>BIAS in measurement of outcomes</bold></td><td align="left"><bold>BIAS in selection of reported result</bold></td><td align="left"><bold>Overall risk BIAS</bold></td></tr><tr><td align="left"><bold>Crane et al. (2023)</bold></td><td align="left">CLL</td><td align="left">B</td><td align="left">Serious</td><td align="left">Low</td><td align="left">Moderate</td><td align="left">Serious</td><td align="left">Moderate</td><td align="left">Low</td><td align="left">Serious</td><td align="left">Serious</td></tr><tr><td align="left"><bold>Artese et al. (2022)</bold></td><td align="left">CLL</td><td align="left">B</td><td align="left">Moderate</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Moderate</td></tr><tr><td align="left"><bold>Macdonald et al. (2021)</bold></td><td align="left">CLL</td><td align="left">A</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td></tr><tr><td align="left"/><td align="left"/><td align="left"><bold>CONSORT</bold></td><td align="left" colspan="8"><bold>RoB 2</bold></td></tr><tr><td align="left"/><td align="left"/><td align="left"><bold>Study quality</bold></td><td align="left"><bold>BIAS due to randomization process</bold></td><td align="left"><bold>BIAS due to deviations from intended interventions</bold></td><td align="left"><bold>BIAS due to missing outcome data</bold></td><td align="left"><bold>BIAS in measurement of outcomes</bold></td><td align="left"><bold>BIAS in selection of reported result</bold></td><td align="left"><bold>Overall risk BIAS</bold></td><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Persoon et al. (2017)</bold></td><td align="left">Multiple myeloma and lymphoma</td><td align="left">A</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Some concerns</td><td align="left">Low</td><td align="left">Some concerns</td><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Furzer et al. (2016)</bold></td><td align="left">HL, NHL and myeloma</td><td align="left">B</td><td align="left">Some concerns</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Some concerns</td><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Courneya et al. (2009)</bold></td><td align="left">HL and NHL</td><td align="left">A</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left"/><td align="left"/></tr></tbody></table></table-wrap></p><p id="Par32">From the 326 participants included in the selected studies, only 22.1% of the sample corresponds to CLL patients, 54.6% refers to non-Hodgkin&#x02019;s lymphoma, 19.0% refers to multiple myeloma, and 4.3% refers to Hodgkin&#x02019;s lymphoma. Most of the studies include patients with median age around 50 years old, with body fat above the limits for age [<xref ref-type="bibr" rid="CR46">46</xref>], and BMI in overweight range. Time for inclusion after diagnosis ranged between 2.1&#x02009;&#x000b1;&#x02009;2.6 and 7.9&#x02009;&#x000b1;&#x02009;9.1 years. In the two studies that engaged CLL patients without previous treatment [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR42">42</xref>], patients recruited were in Rai stage 0 or I (83.3% of patients in intervention group and 80.0% in control group, remaining percentage are described as unknown) or CLL-IPI stage 0&#x02013;1 and 2&#x02013;3 (50.0% of patients in intervention group and 30.0% in control group, remaining percentage are described as unknown). In the remaining studies, this information is not addressed by the authors. Table <xref rid="Tab2" ref-type="table">2</xref> summarizes the baseline overview of the population.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Baseline overview of the population. Data are presented as mean&#x02009;&#x000b1;&#x02009;standard deviation or as median (range). HIIT high-intensity interval training. BMI body mass index</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2"><bold>Crane et al. (2023)</bold></th><th align="left" colspan="2"><bold>Artese et al. (2022)</bold></th><th align="left" colspan="2"><bold>Macdonald et al. (2021)</bold></th><th align="left" colspan="2"><bold>Persoon et al. (2017)</bold></th><th align="left" colspan="2"><bold>Furzer et al. (2016)</bold></th><th align="left" colspan="2"><bold>Courneya et al. (2009)</bold></th></tr><tr><th align="left">Intervention protocol</th><th align="left">Baseline</th><th align="left">Intervention protocol</th><th align="left">Control</th><th align="left">Intervention protocol</th><th align="left">Control</th><th align="left">Intervention protocol</th><th align="left">Control</th><th align="left">Intervention protocol</th><th align="left">Control</th><th align="left">Intervention protocol</th><th align="left">Control</th></tr></thead><tbody><tr><td align="left"><bold>Intervention characteristics</bold></td><td align="left" colspan="2">Home-based aerobic only or aerobic with resistance exercises</td><td align="left">HIIT</td><td align="left">Usual care</td><td align="left">HIIT</td><td align="left">Usual care</td><td align="left">HIIT&#x02009;+&#x02009;resistance Ex</td><td align="left">Usual care</td><td align="left">Aerobic&#x02009;+&#x02009;resistance Ex</td><td align="left">Usual care</td><td align="left">Aerobic exercise training</td><td align="left">Usual care</td></tr><tr><td align="left" colspan="13"><bold>Demographics</bold></td></tr><tr><td align="left">&#x02003;Age (yrs.)</td><td align="left" colspan="2">63.04&#x02009;&#x000b1;&#x02009;8.67</td><td align="left">62.2&#x02009;&#x000b1;&#x02009;9.4</td><td align="left">66.5&#x02009;&#x000b1;&#x02009;7.1</td><td align="left">63.9&#x02009;&#x000b1;&#x02009;10.8</td><td align="left">66.5&#x02009;&#x000b1;&#x02009;7.1</td><td align="left">53.5 (20&#x02013;67)</td><td align="left">56 (19&#x02013;67)</td><td align="left">48.2&#x02009;&#x000b1;&#x02009;12.3</td><td align="left">49.6&#x02009;&#x000b1;&#x02009;14.1</td><td align="left">51.2 (18&#x02013;77)</td><td align="left">53.5 (18&#x02013;80)</td></tr><tr><td align="left">&#x02003;Sex (m/f)</td><td align="left" colspan="2">16/8</td><td align="left">3/6</td><td align="left">4/2</td><td align="left">4/6</td><td align="left">4/2</td><td align="left">32/22</td><td align="left">37/18</td><td align="left">18 (unknown m/f ratio)</td><td align="left">19 (unknown m/f ratio)</td><td align="left">37/23</td><td align="left">35/27</td></tr><tr><td align="left">&#x02003;BMI (kg/m<sup>2</sup>)</td><td align="left">27.4&#x02009;&#x000b1;&#x02009;5.07</td><td align="left">27.8&#x02009;&#x000b1;&#x02009;4.83</td><td align="left">27.3&#x02009;&#x000b1;&#x02009;7</td><td align="left">25.4&#x02009;&#x000b1;&#x02009;3.1</td><td align="left">27.3&#x02009;&#x000b1;&#x02009;6.6</td><td align="left">25.4&#x02009;&#x000b1;&#x02009;3.1</td><td align="left">25.6&#x02009;&#x000b1;&#x02009;4.6</td><td align="left">25.1&#x02009;&#x000b1;&#x02009;3.6</td><td align="left">24.2&#x02009;&#x000b1;&#x02009;3.3</td><td align="left">25.8&#x02009;&#x000b1;&#x02009;4.7</td><td align="left">27.4&#x02009;&#x000b1;&#x02009;4.5</td><td align="left">26.7&#x02009;&#x000b1;&#x02009;5.4</td></tr><tr><td align="left">&#x02003;Lean mass (kg)</td><td align="left" colspan="2"/><td align="left"/><td align="left"/><td align="left">48.2&#x02009;&#x000b1;&#x02009;12.4</td><td align="left">53.7&#x02009;&#x000b1;&#x02009;10.5</td><td align="left"/><td align="left"/><td align="left">48.34&#x02009;&#x000b1;&#x02009;10.33</td><td align="left">46.85&#x02009;&#x000b1;&#x02009;10.21</td><td align="left">52.4&#x02009;&#x000b1;&#x02009;10.9</td><td align="left">49.9&#x02009;&#x000b1;&#x02009;10.0</td></tr><tr><td align="left">Body fat (%)</td><td align="left" colspan="2"/><td align="left"/><td align="left"/><td align="left">37.7&#x02009;&#x000b1;&#x02009;10.3</td><td align="left">31.0&#x02009;&#x000b1;&#x02009;10.3</td><td align="left"/><td align="left"/><td align="left">29.79&#x02009;&#x000b1;&#x02009;9.20</td><td align="left">34.56&#x02009;&#x000b1;&#x02009;11.16</td><td align="left">32.6&#x02009;&#x000b1;&#x02009;9.9</td><td align="left">32.6&#x02009;&#x000b1;&#x02009;10.9</td></tr><tr><td align="left" colspan="13"><bold>Disease characteristics</bold></td></tr><tr><td align="left">&#x02003;Chronic lymphocytic leukemia (N/total sample)</td><td align="left" colspan="2">24/24</td><td align="left">9/9</td><td align="left">6/6</td><td align="left">10/10</td><td align="left">6/6</td><td align="left">Unknown/54</td><td align="left">Unknown/55</td><td align="left">Unknown/18</td><td align="left">Unknown/19</td><td align="left">4/60</td><td align="left">10/62</td></tr><tr><td align="left">&#x02003;Time since diagnose (yrs)</td><td align="left" colspan="2"/><td align="left">7.9&#x02009;&#x000b1;&#x02009;9.1</td><td align="left">4.6&#x02009;&#x000b1;&#x02009;4.3</td><td align="left">7.3&#x02009;&#x000b1;&#x02009;8.7</td><td align="left">4.6&#x02009;&#x000b1;&#x02009;4.3</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">2.1&#x02009;&#x000b1;&#x02009;2.6</td><td align="left">2.8&#x02009;&#x000b1;&#x02009;3.3</td></tr><tr><td align="left">&#x02003;Prior treatment (N/total sample)</td><td align="left" colspan="2">9/24</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Ongoing treatment (N/total sample)</td><td align="left" colspan="2">12/24</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="13">Rai stage (N)</td></tr><tr><td align="left">&#x02003;0</td><td align="left" colspan="2">7</td><td align="left">6</td><td align="left">4</td><td align="left">7</td><td align="left">4</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">16</td><td align="left">18</td></tr><tr><td align="left">&#x02003;I&#x02009;+&#x02009;</td><td align="left" colspan="2">17</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">43</td><td align="left">43</td></tr><tr><td align="left">&#x02003;Unknown</td><td align="left" colspan="2"/><td align="left">2</td><td align="left">1</td><td align="left">2</td><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">1</td><td align="left">1</td></tr><tr><td align="left">&#x02003;CLL-IPI (N)</td><td align="left" colspan="2"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;0&#x02013;1</td><td align="left" colspan="2"/><td align="left"/><td align="left"/><td align="left">2</td><td align="left">2</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;2&#x02013;3</td><td align="left" colspan="2"/><td align="left"/><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Unknown</td><td align="left" colspan="2"/><td align="left"/><td align="left"/><td align="left">7</td><td align="left">3</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr></tbody></table></table-wrap></p><p id="Par33">The duration of intervention was predominantly 12 weeks with 2&#x02013;3 training days per week, except for the Persoon et al. [<xref ref-type="bibr" rid="CR45">45</xref>] intervention which lasted 18 weeks, and Crane et al. [<xref ref-type="bibr" rid="CR32">32</xref>] that lasted 16 weeks. The main outcomes were associated with health-related quality of life questionnaires (reported in 4 studies), objective measured physical activity (reported in 4 studies), and immune characteristics (reported in 2 studies). On physical activity outcomes, the most analysed parameter was the cardiovascular outcomes, but with different characterizations. Crane et al. [<xref ref-type="bibr" rid="CR32">32</xref>] used a home-based exercise program using 16 combinations of exercises but do not clearly describe the frequency, intensity, time and type (FITT) principles of exercise prescription. Artese et al. [<xref ref-type="bibr" rid="CR42">42</xref>] did not present data about this parameter but concatenated to another study [<xref ref-type="bibr" rid="CR33">33</xref>] where data was collected from. Equipment&#x02019;s used were treadmill and upright or recumbent cycle ergometer. Regarding muscular parameters, Courneya et al. [<xref ref-type="bibr" rid="CR43">43</xref>] did not present any outcome, while others presented data regarding muscle strength, muscle endurance, or maximal torque. It was also assessed the physical activity with accelerometry technology in Persoon et al. [<xref ref-type="bibr" rid="CR45">45</xref>], and leisure time activity (by questionnaire) as well as bone mineral density in the study by Furzer et al. [<xref ref-type="bibr" rid="CR44">44</xref>]. Table <xref rid="Tab3" ref-type="table">3</xref> presented the characteristics of the included studies with physical intervention.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Characteristics of the included studies with intervention. ND not described, MSEC maximal short exercise capacity (using steep ramp test), 1RM 1 repetition maximum, HRR heart rate reserve, CV cardiovascular training, HIIT high-intensity interval training, REx resistance exercise</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study</th><th align="left">Sample size</th><th align="left">Exercise duration and frequency</th><th align="left">Aerobic mode</th><th align="left">Aerobic intensity</th><th align="left">Aerobic interval</th><th align="left">Aerobic recovery</th><th align="left">Resistance mode</th><th align="left">Resistance intensity</th><th align="left">Resistance interval</th><th align="left">Resistance recovery</th><th align="left">Supervised OR unsupervised</th></tr></thead><tbody><tr><td align="left">Crane et al. (2023)</td><td align="left">24</td><td align="left">16&#x000a0;weeks, combination of home-exercise routines</td><td align="left">ND</td><td align="left">ND</td><td align="left">ND</td><td align="left">ND</td><td align="left">ND</td><td align="left">ND</td><td align="left">ND</td><td align="left">ND</td><td align="left">Unsupervised and self-reported</td></tr><tr><td align="left">Artese et al. (2022)</td><td align="left">15</td><td align="left">12&#x000a0;weeks, 3&#x02009;&#x000d7;&#x02009;/week (2&#x02009;&#x000d7;&#x02009;HIIT&#x02009;+&#x02009;REx and 1&#x02009;&#x000d7;&#x02009;only HIIT)</td><td align="left">Treadmill</td><td align="left"><p>Warm-up: 5&#x000a0;min</p><p>Work phase: 80&#x02013;90% HRR</p><p>Cool down: 5&#x000a0;min</p></td><td align="left">60&#x02013;90&#x000a0;s work followed by 60&#x02013;90&#x000a0;s active recovery until complete m&#x000e1;x 20&#x000a0;min</td><td align="left">50&#x02013;60% HRR</td><td align="left">Major muscle groups using machines (leg press, chest press, seated row)</td><td align="left"><p>Warm-up: 10 rep at 40&#x02013;60% of 1RM</p><p>Work phase: Many reps possible at 70% of 1RM for 2 sets</p></td><td align="left">ND</td><td align="left">ND</td><td align="left">Supervised by exercise physiologist</td></tr><tr><td align="left">Macdonald et al. (2021)</td><td align="left">16</td><td align="left">12&#x000a0;weeks, 3&#x02009;&#x000d7;&#x02009;/week (2&#x02009;&#x000d7;&#x02009;HIIT&#x02009;+&#x02009;Rex and 1&#x02009;&#x000d7;&#x02009;only HIIT)</td><td align="left">Treadmill</td><td align="left"><p>Warm-up: 5&#x000a0;min</p><p>Work phase: 80&#x02013;90% VO2 reserve</p><p>Cool down: 5&#x000a0;min</p></td><td align="left">60&#x02013;90&#x000a0;s work followed by 60&#x02013;90&#x000a0;s active recovery until complete m&#x000e1;x 20&#x000a0;min</td><td align="left">50&#x02013;60% VO2 reserve</td><td align="left">Major muscle groups using machines (leg press, chest press, seated row)</td><td align="left"><p>Warm-up: 10 rep at 40&#x02013;60% of 1RM</p><p>Work phase: Many reps possible at 70% of 1RM for 2 sets</p></td><td align="left">ND</td><td align="left">ND</td><td align="left">Supervised by exercise physiologist</td></tr><tr><td align="left">Persoon et al. (2017)</td><td align="left">109</td><td align="left"><p>18&#x000a0;weeks, from 1&#x02013;12&#x000a0;weeks 2&#x02009;&#x000d7;&#x02009;/week</p><p>From 13&#x02013;18&#x000a0;weeks 1&#x02009;&#x000d7;&#x02009;/week</p></td><td align="left">Cycle ergometer</td><td align="left">65% MSEC</td><td align="left"><p>2&#x02009;&#x000d7;&#x02009;blocks of 8&#x000a0;min (MSEC)</p><p>Week 1&#x02013;8: 30&#x000a0;s work 60&#x000a0;s active rest</p><p>Week 9&#x02013;18: 30&#x000a0;s work 30&#x000a0;s active rest</p></td><td align="left">30% MSEC</td><td align="left">4 standardized exercises (vertical row, leg press, bench/chest press, pullover/flies) and 2 exercises for abdominal muscles and upper legs</td><td align="left"><p>Week 1&#x02013;12: 65&#x02013;80% 1RM</p><p>Week 13&#x02013;18: 35&#x02013;40% 1RM</p></td><td align="left"><p>Week 1&#x02013;12: 2 sets of 10 rep</p><p>Week: 13&#x02013;18: 2 sets of 20 rep</p></td><td align="left">ND</td><td align="left">Supervised by instructed physiotherapists</td></tr><tr><td align="left">Furzer et al. (2016)</td><td align="left">37</td><td align="left">12&#x000a0;weeks, 3&#x02009;&#x000d7;&#x02009;/week</td><td align="left">ND</td><td align="left"><p>Initial phase: 50% of HRmax</p><p>Progression phase: 5% weekly increment until reach 85% HRmax</p></td><td align="left">Max 30&#x000a0;min continuous CV training</td><td align="left"/><td align="left">6 machines and 2 dumbbell targeting major muscle groups</td><td align="left"><p>Initial load: 50% 1RM</p><p>Aimed load: 80% 1RM</p></td><td align="left"><p>Initial load: 3 sets of 10&#x02013;15 rep</p><p>Aimed load: 2 to 3 sets of 6&#x02013;8 rep</p></td><td align="left">Minimum of 90&#x000a0;s recovery between sets</td><td align="left">Supervised by exercise physiologist</td></tr><tr><td align="left">Courneya et al. (2009)</td><td align="left">122</td><td align="left">12&#x000a0;weeks, 3&#x02009;&#x000d7;&#x02009;/week</td><td align="left">Upright or recumbent cycle ergometer</td><td align="left">60&#x02013;75% VO2 peak</td><td align="left">15&#x02013;45&#x000a0;min continuous CV training</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">Supervised by exercise physiologist</td></tr></tbody></table></table-wrap></p><p id="Par34">Although meta-analysis was not feasible due to the heterogeneity of interventions, populations, and outcome measures across the included studies, the following tables summarize key findings and trends observed in the data. The results are presented focusing on physical parameters and health-related quality of life (HRQoL) outcomes, with particular attention to the effects of the interventions.</p><p id="Par35">Regarding physical parameters, the included studies report a variety of physical outcomes, including VO2peak, muscle strength, body composition, and functional tests (e.g., 6-min walk test, timed up and go). Across studies, most results show improvements in the intervention groups compared to control, though not all reach statistical significance. Macdonald et al. [<xref ref-type="bibr" rid="CR33">33</xref>] and Persoon et al. [<xref ref-type="bibr" rid="CR45">45</xref>] observed significant improvements in VO2 peak in the intervention groups compared to controls (from 21&#x02009;&#x000b1;&#x02009;04 to 22&#x02009;&#x000b1;&#x02009;07 L/min and from 24&#x02009;&#x000b1;&#x02009;7 to 28&#x02009;&#x000b1;&#x02009;7 mL/kg/min, respectively), indicating enhanced aerobic capacity after HIIT and resistance training. Several studies noted increases in muscle strength, particularly in leg and chest press exercises. Even Crane et al. [<xref ref-type="bibr" rid="CR32">32</xref>] home-based exercise intervention reported an increase from 112&#x02009;&#x000b1;&#x02009;37 to 153&#x02009;&#x000b1;&#x02009;46 kg in leg strength. These improvements suggest positive adaptations to both aerobic and resistance exercise protocols. Regarding body composition, there were no significant changes in body fat percentage or lean mass in most studies. This indicates that while functional and aerobic capacity improved, body composition remained relatively stable across interventions. Table <xref rid="Tab4" ref-type="table">4</xref> summarizes the objectively assessed physical parameters for each study.
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Objectively assessed physical parameters described as mean&#x02009;&#x000b1;&#x02009;standard deviation. Bold text indicates non-statistical differences between groups. Because of the risk of recruitment bias, MacDonald et al. (2021) study did not report <italic>p</italic>-values throughout, so bold text represents small-medium effects size&#x02009;&#x0003c;&#x02009;0,5 Hedges&#x02019;G</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2"><bold>Crane et al. (2023)</bold></th><th align="left" colspan="2"><bold>Macdonald et al. (2021) (and Artese et al. (2022))</bold></th><th align="left" colspan="2"><bold>Persoon et al. (2017)</bold></th><th align="left" colspan="2"><bold>Furzer et al. (2016)</bold></th><th align="left" colspan="2"><bold>Courneya et al. (2009)</bold></th></tr><tr><th align="left">T0</th><th align="left">T1</th><th align="left">T0</th><th align="left">T1</th><th align="left">T0</th><th align="left">T1</th><th align="left">T0</th><th align="left">T1</th><th align="left">T0</th><th align="left">T1</th></tr></thead><tbody><tr><td align="left"><bold>Leisure time activity (questionnaires)</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">816&#x02009;&#x000b1;&#x02009;537</td><td align="left">1964&#x02009;&#x000b1;&#x02009;1236</td><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Accelerometry (cpm)</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>189.0&#x02009;&#x000b1;&#x02009;79.2</bold></td><td align="left"><bold>241.4&#x02009;&#x000b1;&#x02009;92.3</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>PASE-score</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>96.9&#x02009;&#x000b1;&#x02009;99.5</bold></td><td align="left"><bold>131.3&#x02009;&#x000b1;&#x02009;82.4</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>VO2 peak (ml/kg/min)</bold></td><td align="left"/><td align="left"/><td align="left"><bold>26.7&#x02009;&#x000b1;&#x02009;6.1</bold></td><td align="left"><bold>28.5&#x02009;&#x000b1;&#x02009;5.5</bold></td><td align="left"><bold>21.7&#x02009;&#x000b1;&#x02009;4.8</bold></td><td align="left"><bold>26.0&#x02009;&#x000b1;&#x02009;6.3</bold></td><td align="left"/><td align="left"/><td align="left">24.7&#x02009;&#x000b1;&#x02009;7.2</td><td align="left">29.4&#x02009;&#x000b1;&#x02009;8.6</td></tr><tr><td align="left"><bold>VO2 peak (L/min)</bold></td><td align="left"/><td align="left"/><td align="left"><bold>2.1&#x02009;&#x000b1;&#x02009;0.4</bold></td><td align="left"><bold>2.2&#x02009;&#x000b1;&#x02009;0.7</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">2.02&#x02009;&#x000b1;&#x02009;0.66</td><td align="left">2.38&#x02009;&#x000b1;&#x02009;0.81</td></tr><tr><td align="left"><bold>W peak (Watt/kg)</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>2.0&#x02009;&#x000b1;&#x02009;0.5</bold></td><td align="left"><bold>2.4&#x02009;&#x000b1;&#x02009;0.7</bold></td><td align="left">1.45&#x02009;&#x000b1;&#x02009;0.44</td><td align="left">1.84&#x02009;&#x000b1;&#x02009;0.48</td><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>6&#x000a0;min walk test (m)</bold></td><td align="left"><bold>500.15</bold></td><td align="left"><bold>525.08</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Timed up and go (s)</bold></td><td align="left"><bold>5.58</bold></td><td align="left"><bold>5.67</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="11"><bold>Muscle strength</bold></td></tr><tr><td align="left">&#x02003;Leg</td><td align="left"/><td align="left"/><td align="left"><bold>133.5&#x02009;&#x000b1;&#x02009;30</bold></td><td align="left"><bold>137.9&#x02009;&#x000b1;&#x02009;53.5</bold></td><td align="left"/><td align="left"/><td align="left">112&#x02009;&#x000b1;&#x02009;37</td><td align="left">153&#x02009;&#x000b1;&#x02009;46</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Chest</td><td align="left"/><td align="left"/><td align="left"><bold>48.8&#x02009;&#x000b1;&#x02009;20.2</bold></td><td align="left"><bold>43.2&#x02009;&#x000b1;&#x02009;26.9</bold></td><td align="left"/><td align="left"/><td align="left">32&#x02009;&#x000b1;&#x02009;18</td><td align="left">47&#x02009;&#x000b1;&#x02009;25</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Back</td><td align="left"/><td align="left"/><td align="left">65.7&#x02009;&#x000b1;&#x02009;27.8</td><td align="left">51.2&#x02009;&#x000b1;&#x02009;24.9</td><td align="left"/><td align="left"/><td align="left">52&#x02009;&#x000b1;&#x02009;18</td><td align="left">67&#x02009;&#x000b1;&#x02009;24</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Arms</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">9&#x02009;&#x000b1;&#x02009;4</td><td align="left">12&#x02009;&#x000b1;&#x02009;6</td><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="11"><bold>Muscle endurance (max rep with 70% 1RM)</bold></td></tr><tr><td align="left">&#x02003;Leg</td><td align="left"/><td align="left"/><td align="left"><bold>20.6&#x02009;&#x000b1;&#x02009;4.9</bold></td><td align="left"><bold>20.3&#x02009;&#x000b1;&#x02009;5.7</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Chest</td><td align="left"/><td align="left"/><td align="left"><bold>14.8&#x02009;&#x000b1;&#x02009;1.7</bold></td><td align="left"><bold>14.4&#x02009;&#x000b1;&#x02009;3.5</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Back</td><td align="left"/><td align="left"/><td align="left"><bold>15.8&#x02009;&#x000b1;&#x02009;1.3</bold></td><td align="left"><bold>15.7&#x02009;&#x000b1;&#x02009;3.8</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Chair stand test (number rep)</bold></td><td align="left"><bold>13.5</bold></td><td align="left"><bold>13.5</bold></td><td align="left"/><td align="left"/><td align="left"><bold>15.5&#x02009;&#x000b1;&#x02009;4.6</bold></td><td align="left"><bold>18.7&#x02009;&#x000b1;&#x02009;6.0</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Grip strength (kg)</bold></td><td align="left"><bold>9.67</bold></td><td align="left"><bold>14.00</bold></td><td align="left"/><td align="left"/><td align="left"><bold>35.5&#x02009;&#x000b1;&#x02009;10.7</bold></td><td align="left"><bold>40.9&#x02009;&#x000b1;&#x02009;12</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Maximal torque m. quadr&#x000ed;ceps (Nm)</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>145.6&#x02009;&#x000b1;&#x02009;51.4</bold></td><td align="left"><bold>173.9&#x02009;&#x000b1;&#x02009;55.9</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="11"><bold>Bone mineral density</bold></td></tr><tr><td align="left">&#x02003;AP spine (after 24 wk)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">1.226&#x02009;&#x000b1;&#x02009;0.185</td><td align="left">1.232&#x02009;&#x000b1;&#x02009;0.180</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Femur (after 24 wk)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">1.061&#x02009;&#x000b1;&#x02009;0.170</td><td align="left">1.063&#x02009;&#x000b1;&#x02009;0.170</td><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Lean mass (kg)</bold></td><td align="left"/><td align="left"/><td align="left"><bold>48.2&#x02009;&#x000b1;&#x02009;12.4</bold></td><td align="left"><bold>3.1&#x02009;&#x000b1;&#x02009;5.2 (% change)</bold></td><td align="left"/><td align="left"/><td align="left">48.34&#x02009;&#x000b1;&#x02009;10.33</td><td align="left">50.07&#x02009;&#x000b1;&#x02009;11.35</td><td align="left">52.4&#x02009;&#x000b1;&#x02009;10.9</td><td align="left">52.3&#x02009;&#x000b1;&#x02009;11.5</td></tr><tr><td align="left"><bold>Fat mass (kg)</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>25.8&#x02009;&#x000b1;&#x02009;9.5</bold></td><td align="left"><bold>26.0&#x02009;&#x000b1;&#x02009;10.1</bold></td></tr><tr><td align="left"><bold>Body fat (%)</bold></td><td align="left"/><td align="left"/><td align="left"><bold>37.7&#x02009;&#x000b1;&#x02009;10.3</bold></td><td align="left"><bold>&#x02009;&#x02212;&#x02009;4.9&#x02009;&#x000b1;&#x02009;12.5 (% change)</bold></td><td align="left">SUM SKF &#x021d1;</td><td align="left">SUM SKF &#x021d1;</td><td align="left">29.79&#x02009;&#x000b1;&#x02009;9.20</td><td align="left">28.68&#x02009;&#x000b1;&#x02009;10.56</td><td align="left"><bold>32.6&#x02009;&#x000b1;&#x02009;9.9</bold></td><td align="left"><bold>32.8&#x02009;&#x000b1;&#x02009;10.1</bold></td></tr></tbody></table></table-wrap></p><p id="Par36">Regarding health-related quality of life (HRQoL), a wide range of outcomes was reported using multiple instruments [<xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref>] such as the EORTC QLQ-C30 [<xref ref-type="bibr" rid="CR53">53</xref>], symptom assessment scale [<xref ref-type="bibr" rid="CR54">54</xref>], and functional assessment of cancer therapy [<xref ref-type="bibr" rid="CR55">55</xref>]. Across studies, improvements were noted, particularly in physical functioning, role functioning, and fatigue, though again, not all differences were statistically significant. Crane et al. [<xref ref-type="bibr" rid="CR32">32</xref>] reported significant improvements in fatigue scale (from 37 (IQR, 27.75; 45.75) to 45 (IQR, 39.50; 47.75)). These findings highlight the potential of structured exercise interventions to enhance both physical functioning and overall QoL in cancer survivors. Furzer et al. [<xref ref-type="bibr" rid="CR44">44</xref>] noted positive trends in the FACT-Lym total score (from 81.2&#x02009;&#x000b1;&#x02009;12.8 to 90.2&#x02009;&#x000b1;&#x02009;10.1), suggesting improvements in both physical and emotional well-being following aerobic and resistance exercise training. Courneya et al. [<xref ref-type="bibr" rid="CR43">43</xref>] also found significant statistical differences in FACT-An total score, and in happiness scale and depression scale, reflecting the importance of physical activity in mental health and HRQoL well-being. Table <xref rid="Tab5" ref-type="table">5</xref> summarizes the HRQoL outcomes.
<table-wrap id="Tab5"><label>Table 5</label><caption><p>Health-related quality of life outcomes. Data are shown as sum&#x02009;&#x000b1;&#x02009;std dev or as median (interquartile range). <italic>IQR</italic> interquartile range. Bold text indicates non-statistical differences between groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2"><bold>Crane et al. (2023)</bold></th><th align="left" colspan="2"><bold>Artese et al. (2022)</bold></th><th align="left" colspan="2"><bold>Macdonald et al. (2021)</bold></th><th align="left" colspan="2"><bold>Persoon et al. (2017)</bold></th><th align="left" colspan="2"><bold>Furzer et al. (2016)</bold></th><th align="left" colspan="2"><bold>Courneya et al. (2009)</bold></th></tr><tr><th align="left">T0</th><th align="left">T1</th><th align="left">T0</th><th align="left">T1</th><th align="left">T0</th><th align="left">T1</th><th align="left">T0</th><th align="left">T1</th><th align="left">T0</th><th align="left">T1</th><th align="left">T0</th><th align="left">T1</th></tr></thead><tbody><tr><td align="left"><bold>HADS&#x02013;anxiety </bold>[<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>4.4&#x02009;&#x000b1;&#x02009;3.5</bold></td><td align="left"><bold>4.1&#x02009;&#x000b1;&#x02009;4.1</bold></td><td align="left"><bold>5.3&#x02009;&#x000b1;&#x02009;2.9</bold></td><td align="left"><bold>5.0&#x02009;&#x000b1;&#x02009;3.9</bold></td><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>HADS&#x02013;depression </bold>[<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>3.8&#x02009;&#x000b1;&#x02009;3.8</bold></td><td align="left"><bold>3.2&#x02009;&#x000b1;&#x02009;3.4</bold></td><td align="left"><bold>4.7&#x02009;&#x000b1;&#x02009;3.4</bold></td><td align="left"><bold>2.4&#x02009;&#x000b1;&#x02009;2.2</bold></td><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>SCFS&#x02013;fatigue </bold>[<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">13.7&#x02009;&#x000b1;&#x02009;4.4</td><td align="left">9.3&#x02009;&#x000b1;&#x02009;2.0</td><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>PCS (SF-36)-physical component </bold>[<xref ref-type="bibr" rid="CR49">49</xref>]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">43&#x02009;&#x000b1;&#x02009;10</td><td align="left">52.6&#x02009;&#x000b1;&#x02009;6</td><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Anxiety </bold>[<xref ref-type="bibr" rid="CR50">50</xref>]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>18.4&#x02009;&#x000b1;&#x02009;6.6</bold></td><td align="left"><bold>16.5&#x02009;&#x000b1;&#x02009;5.2</bold></td></tr><tr><td align="left"><bold>Depression </bold>[<xref ref-type="bibr" rid="CR51">51</xref>]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">7.7&#x02009;&#x000b1;&#x02009;5.7</td><td align="left">5.4&#x02009;&#x000b1;&#x02009;4.5</td></tr><tr><td align="left"><bold>Happiness scale </bold>[<xref ref-type="bibr" rid="CR52">52</xref>]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">59&#x02009;&#x000b1;&#x02009;22.4</td><td align="left">70.9&#x02009;&#x000b1;&#x02009;16.4</td></tr><tr><td align="left" colspan="13"><bold>EORTC-QLQ30 </bold>[<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr><td align="left">Global quality of life</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>62.2&#x02009;&#x000b1;&#x02009;18</bold></td><td align="left"><bold>75.0&#x02009;&#x000b1;&#x02009;18.7</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Physical functioning</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>74.5&#x02009;&#x000b1;&#x02009;18.3</bold></td><td align="left"><bold>83.1&#x02009;&#x000b1;&#x02009;19.1</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Role functioning</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>60&#x02009;&#x000b1;&#x02009;31.6</bold></td><td align="left"><bold>81.0&#x02009;&#x000b1;&#x02009;23.8</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Emotional functioning</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>83.2&#x02009;&#x000b1;&#x02009;14.9</bold></td><td align="left"><bold>86.2&#x02009;&#x000b1;&#x02009;16.3</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Cognitive functioning</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>87.3&#x02009;&#x000b1;&#x02009;15.6</bold></td><td align="left"><bold>83.7&#x02009;&#x000b1;&#x02009;18.0</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Social functioning</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>71.7&#x02009;&#x000b1;&#x02009;27.2</bold></td><td align="left"><bold>86.0&#x02009;&#x000b1;&#x02009;20.3</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Disease symptoms</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>16.6&#x02009;&#x000b1;&#x02009;13.1</bold></td><td align="left"><bold>18.7&#x02009;&#x000b1;&#x02009;12.8</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="13"><bold>Fatigue (MFI) </bold>[<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td align="left">Physical fatigue</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>13.2&#x02009;&#x000b1;&#x02009;4.2</bold></td><td align="left"><bold>9.8&#x02009;&#x000b1;&#x02009;4.4</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">General fatigue</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>12.7&#x02009;&#x000b1;&#x02009;3.8</bold></td><td align="left"><bold>10.0&#x02009;&#x000b1;&#x02009;4.5</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Mental fatigue</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>10.0&#x02009;&#x000b1;&#x02009;4.3</bold></td><td align="left"><bold>9.7&#x02009;&#x000b1;&#x02009;4.5</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Reduced activity</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>12.2&#x02009;&#x000b1;&#x02009;4.1</bold></td><td align="left"><bold>9.6&#x02009;&#x000b1;&#x02009;3.9</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Reduced motivation</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>8.8&#x02009;&#x000b1;&#x02009;3.8</bold></td><td align="left"><bold>8.0&#x02009;&#x000b1;&#x02009;3.2</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="13"><bold>FACT </bold>[<xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr><td align="left">Physical well-being</td><td align="left"/><td align="left"/><td align="left"><bold>24.9&#x02009;&#x000b1;&#x02009;3.2</bold></td><td align="left"><bold>25.6&#x02009;&#x000b1;&#x02009;2.1</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Social well-being</td><td align="left"/><td align="left"/><td align="left"><bold>23.0&#x02009;&#x000b1;&#x02009;3.2</bold></td><td align="left"><bold>24.6&#x02009;&#x000b1;&#x02009;2.9</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Emotional well-being</td><td align="left"/><td align="left"/><td align="left"><bold>19.6&#x02009;&#x000b1;&#x02009;2.7</bold></td><td align="left"><bold>20.6&#x02009;&#x000b1;&#x02009;2.2</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Functional well-being</td><td align="left"/><td align="left"/><td align="left">21.7&#x02009;&#x000b1;&#x02009;3.4</td><td align="left">23.9&#x02009;&#x000b1;&#x02009;3.2</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Lymphoma subscale</td><td align="left"/><td align="left"/><td align="left"><bold>49.3&#x02009;&#x000b1;&#x02009;3.9</bold></td><td align="left"><bold>53.3&#x02009;&#x000b1;&#x02009;4.2</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"><bold>47.4&#x02009;&#x000b1;&#x02009;8.7</bold></td><td align="left"><bold>50.3&#x02009;&#x000b1;&#x02009;7.2</bold></td></tr><tr><td align="left">FACT-G total</td><td align="left"/><td align="left"/><td align="left"><bold>89.2&#x02009;&#x000b1;&#x02009;6.6</bold></td><td align="left"><bold>94.6&#x02009;&#x000b1;&#x02009;5.5</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">81.2&#x02009;&#x000b1;&#x02009;12.8</td><td align="left">90.2&#x02009;&#x000b1;&#x02009;10.1</td><td align="left"/><td align="left"/></tr><tr><td align="left">FACT-lym total</td><td align="left"/><td align="left"/><td align="left"><bold>138.6&#x02009;&#x000b1;&#x02009;9.4</bold></td><td align="left"><bold>147.9&#x02009;&#x000b1;&#x02009;6.7</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">FACT-An total</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">140.7&#x02009;&#x000b1;&#x02009;26.8</td><td align="left">151.4&#x02009;&#x000b1;&#x02009;21.7</td></tr><tr><td align="left">FACT fatigue</td><td align="left"><p>Median 37.00</p><p>IQR (27.75; 45.75)</p></td><td align="left"><p>Median 45.00</p><p>IQR (39.50; 47.75)</p></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr></tbody></table></table-wrap></p><p id="Par37">While statistical significance was not reached in all studies, particularly due to small sample sizes, the effect sizes (Hedges&#x02019; G) suggest that moderate improvements were achieved in most physical and QoL outcomes. The results in bold within the tables indicate non-significant findings, yet effect sizes suggest potential clinical relevance, especially in aerobic capacity and muscle strength.</p><p id="Par38">Although meta-analysis was not performed, the overall trends observed in these studies support the effectiveness of combined aerobic and resistance exercise interventions in improving aerobic capacity, muscle strength, and quality of life in cancer patients and survivors. However, the small sample sizes and the variability in outcomes measured across studies limited the ability to conduct a formal meta-analysis. The results nonetheless indicate positive trends that warrant further investigation in larger, more homogeneous samples.</p></sec><sec id="Sec7"><title>Discussion</title><p id="Par39">This systematic review sought to critically assess the available evidence on the relationship between physical activity (particularly HIIT and resistance training) and chronic lymphocytic leukemia, regarding fitness, health-related quality of life and feasibility, and immunologic parameters. Only 6 papers met our search criterion, with 2 addressing the HIIT type of physical activity intervention. Meta-analysis was not feasible due to the heterogeneity of interventions, populations, and outcome measures across the included studies but key findings and trends are reported.</p><p id="Par40">Most of CLL studies were conducted throughout the last two decades, and before 2009, no intervention studies were reported, only observational using questionnaires and involving anthropometric parameters such as height, weight, waist and hip circumference, or the body mass index [<xref ref-type="bibr" rid="CR56">56</xref>&#x02013;<xref ref-type="bibr" rid="CR58">58</xref>]. And because we are still in an early bird phase, many methodological problems are biasing results. Early meta-analysis in 2009 addressed resistance training in cancer survivors and displayed post training improvements in cardiopulmonary function from 6 to 39%, and increases in muscle strength between 11 and 110% [<xref ref-type="bibr" rid="CR59">59</xref>]. We hypothesize that this disparity may be explained by factors such as the contribution of learning effect, variability in strength exercises, intensities and duration of exercise programs, genetic differences, type and stage of cancer, diverse cancer treatments, and the time elapsed since cancer diagnosis. This shows the importance of knowing the progress path between sedentary behaviour and physical active behaviour, and the interconnection with patient&#x02019;s physical active before and after diagnosis.</p><p id="Par41">There is general agreement in the absence of adverse training effects on immunological, endocrinological, and hematopoietic variables, or lymphedema. Moreover, it seems that even high training intensities have been well-tolerated in cancer survivors [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par42">A recent systematic review and meta-analysis confirmed that, in addition to clinical stage evaluation [<xref ref-type="bibr" rid="CR60">60</xref>], the best practice to initial prognosis in CLL patients should include the chronic lymphocytic leukemia international prognostic index (CLL-IPI), which combines 5 parameters (age, clinical stage, <italic>TP53</italic> status, IGHV mutational status, and serum B2-microglobuli) [<xref ref-type="bibr" rid="CR61">61</xref>]. In the studies of our review, only Macdonald et al. (2021) implemented CLL-IPI, while Artese et al. (2022) and Courneya et al. (2009) used Rai staging.</p><p id="Par43">The consistency of &#x0201c;best practice on evaluation&#x0201d; in the physical fitness evaluation is not met, leading to inconclusive data and poor strength evidence. Investigations until this date support intensive endurance exercise, known to induce lymphocyte apoptosis affecting the immune system [<xref ref-type="bibr" rid="CR19">19</xref>]; regular resistance exercise, who can decrease oxidative stress which may lead to attenuate apoptosis related protein [<xref ref-type="bibr" rid="CR20">20</xref>]; high-intensity interval training suggesting that it may be able to delete mainly highly differentiated T cells, known to affect immunity to control latent infections [<xref ref-type="bibr" rid="CR21">21</xref>]. However, for the same physical fitness outcomes, cardiovascular protocols differ in equipment (treadmill or recumbent cycle ergometer); in intensity (90% VO2 reserve, or 90% HR reserve, or 65% maximal short exercise capacity, or HR maximal, or VO2 peak); on duration (20 min interval training, 15&#x02013;45 min continuous, 30 min continuous, 8 min intervals); and on recovery (60&#x02013;90 s active recovery, 30&#x02013;60 s active recovery, no recovery). Muscular protocols differ in resistance mode (major muscle groups using machines, or dumbbells, or calisthenic exercises); resistance intensity (70% of 1-RM for maximal repetitions, 80% of 1-RM for 6&#x02013;8 repetitions, 65&#x02013;80% 1-RM); duration of effort (2 sets of 10 repetitions, 2&#x02013;3 sets of 6&#x02013;8 repetitions, 2 sets of 20 repetitions); and recovery (minimum of 90 s between sets, or not described at all). For the goodness of proof, it is mandatory that gold-standard equipment&#x02019;s are used, such as isokinetic dynamometers to evaluate muscular effort, cardiopulmonary exercise test (CPET) with electrocardiogram to assess cardiac and pulmonary response, dual-energy X-ray absorptiometry (DEXA) to evaluate corporal composition.</p><p id="Par44">In the studies with intervention protocols available, one was based only on recumbent cycle ergometer training, regarding heart rate reserve as modulator of intensity [<xref ref-type="bibr" rid="CR43">43</xref>], three studies with HIIT exclusively during 30 min, or with 1 h combining 30 min HIIT plus 30 min resistance training [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR45">45</xref>], and another study using continuous cardiovascular training concomitant with resistance training [<xref ref-type="bibr" rid="CR44">44</xref>]. However, because there is a combination of continuous cardiovascular (or HIIT) plus RT, we cannot fully establish a relation between resistance/strength training only, and cardiovascular only, or the combined effect of training in CLL patients, neither infer about the difference between endurance and strength training in resistance training protocols. Nevertheless, findings showed that more than 12-weeks of training, with more than 30 min. of HIIT combined with muscle endurance-based resistance training for treatment na&#x000ef;ve CLL patients, is feasible and is associated with significant effects on muscle strength and normal immune cell functions [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR45">45</xref>].</p><p id="Par45">Corroborated from current knowledge, urges the need to clarify the exercise characteristics and outcomes regarding HIIT, resistance training (also between strength and endurance approaches) and combined training in CLL patients. The difference between muscular endurance training (more repetitions, and fatigue resistance to exercise) and maximum strength training (increment in muscle strength and/or muscle hypertrophy) must also be assessed. Most studies use DEXA and BIA for body composition analysis, which are indirect measures, insensitive to changes in muscle size, that consequently would keep very small changes from muscle hypertrophy adaptations undetected [<xref ref-type="bibr" rid="CR62">62</xref>]. As described elsewhere [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>], when volume is equated, resistance training frequency does not significantly or meaningfully impact muscle hypertrophy. However, higher training frequencies can help to accumulate more significant volumes of training, which may enhance hypertrophic response.</p><p id="Par46">The studies obtained in this review shows a preference for low-moderate intensities, or endurance effort on resistance training (65&#x02013;70% of 1-RM), but as literature suggest, exercise-induced myokines production have a critical role in increasing cytotoxicity and the infiltration of immune cells into the tumour [<xref ref-type="bibr" rid="CR25">25</xref>]. When comparing aerobic only, strength only and both guidelines, the hazard ratio for all-cause mortality was lower when combining both guidelines, but when alone, strength training was better than aerobic; in the case of cardiovascular disease mortality, both guidelines combined are still the better choice to a lower hazard ratio; but in cancer mortality, strength only training shows to be the better option compared to combined guidelines [<xref ref-type="bibr" rid="CR65">65</xref>]. There are no studies addressing the use of strength training on CLL patients but given the fact that one of the most evident symptoms as the disease progresses are fatigue and shortness of breath during regular physical activity, it seems reasonable that a strength training is better tolerated than a cardiovascular training. Confirming the feasibility and success of this type/mode of training should be engaged in future studies.</p><p id="Par47">It is also important to objectively assess the daily lifestyle of patients to establish a possible etiology of CLL, implementing the accelerometry technology, to ensure correct lifestyle patterns recommendations, and make a connection point with anatomic/morphologic data (muscular mass, body fat percentage, weight, blood, and cardiovascular parameters), and physical condition (VO2, strength, flexibility, mobility, and more).</p><p id="Par48">Despite the medical conservative approach in leukemic patients regarding exercise prescription, leading exercise oncologists suggest that all cancer patients should avoid inactivity and engage in safe exercise training [<xref ref-type="bibr" rid="CR66">66</xref>]. It was reported in a small cohort with 12 patients with hematologic disease (7 patients with acute myeloid leukemia, 1 acute lymphoblastic leukemia and 4 non-Hodgkin&#x02019;s lymphoma) receiving high-dose chemotherapy, that none of the patients with thrombocyte counts below 10.000/&#x003bc;l suffered bleeding and no patient with haemoglobin counts below 8 g/dl suffered critical tachycardias, showing that physical exercise in patients with severe cytopenia is safe and results in increased physical performance and unchanged quality of life [<xref ref-type="bibr" rid="CR67">67</xref>]. Also in the studies we collected, the feasibility of the intervention protocols were always highly rated, with 99&#x02009;&#x000b1;&#x02009;3.6% attendance and 148.5&#x02009;&#x000b1;&#x02009;5.4 min/week of exercise and with 100% safety [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]; with 91% attendance with 88&#x02009;&#x000b1;&#x02009;17 min/week (Furzer et al., 2016); with small adverse events related with intervention protocol such as back, hip and knee pain (Courneya et al., 2009) but without impairment of patients maintenance on the protocol.</p><p id="Par49">Considering immunologic outcomes, only two small pilot studies compared disease parameters. One revealed a significant effect on NK-cells, including increased absolute counts, cytotoxic function, as well as increased perforin and granzyme B expression, mimicking the response to exercise in subjects without cancer [<xref ref-type="bibr" rid="CR33">33</xref>] while the other enlightened an increased ratio CD4:CD8 T-cell, and reduced proportion of T-cells subsets [<xref ref-type="bibr" rid="CR32">32</xref>]. Although these results should be treated with care since a control group is missing, and patients received treatment before or during intervention with medication known to alter T-cell phenotype and function, this relationship between exercise and immune outcomes should be further explored in future studies. As reported elsewhere [<xref ref-type="bibr" rid="CR68">68</xref>], exercise is an effective modulator in sustaining proliferative signalling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, exercise and tumour-promoting inflammation and reprogramming energy metabolism, evading immune destruction, with myokines playing a significant role in the prevention of cancer proliferation. The effect of exercise in these hallmarks of cancer should be evaluated in CLL cells.</p></sec><sec id="Sec8"><title>Conclusion</title><p id="Par50">This systematic review exposed the gap of few implemented studies and conflicting results in some physical activity approaches in CLL patients. To our knowledge, only three studies specifically addressed CLL patients, but with small samples of patients in pilot study experiments. Nevertheless, it is noted the vital role of exercise before treatment, with significant improvements in physical fitness, and immunologic parameters.</p><p id="Par51">Aerobic exercise training significantly improved objective physical function when worked at 60&#x02013;75% of VO2 peak; aerobic and resistance exercises combined resulted in significant clinical improvements in cardiorespiratory fitness when worked at 85% HRmax and 80% of 1-RM; HIIT combined with muscle endurance-based resistance training is feasible and associated with large effects on muscle strength and immune function when worked at 90% VO2 reserve and 70% of 1-RM; even a home-based physical activity program increased leisure-time PA and decreased fatigue. However, no significant beneficial effects of supervised high-intensity exercise programs on physical fitness and fatigue with intensities of 65% HR and 40% of 1-RM. This suggests that this population do not differ from healthy populations, and it seems to be more beneficial to adjust the intensity of workout to higher limits rather than low limits. Studies addressing strength-based resistance training are inexistent, since all the studies analysed just used endurance-based resistance training programs, or combined programs.</p><p id="Par52">The present literature also shows a gap regarding evaluation process, advising that future studies should include most accurate instruments to address disease parameters: physical exam and health history, complete blood count, blood chemistry studies, lactate dehydrogenase testing, beta-2-microglobulin testing, flow cytometry to quantify tumour markers at cell surface, FISH analyses, gene mutation testing, serum immunoglobulin testing, chest x-ray for organs and bones, CT scan and/or PET-CT scan. Additionally, include reference instruments to evaluate physical fitness components objectively: DEXA scan for body composition, dynamometers for muscular strength or endurance, VO2max protocol with ergospirometry and ECG, O2 saturation, lactate, ultrasound for muscle density, blood pressure, heart rate and accelerometry. The physical activity must be precisely quantified to define the treatment dose of exercise.</p><p id="Par53">The conclusions mentioned here are supported by a short number of studies. Therefore, care should be taken to interpret these findings. To be able to advise Exercise Professionals to prescribe different modes/types of exercise, improving compliance with the prescribed exercise program and determine which intervention in the context of exercise prescription should be used to maximize the benefits resulting from the regular practice of physical activity, more studies are needed to evaluate the impact of PA in the health-related quality of life and life span of the CLL patient.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>PC was responsible for Conceptualization, Methodology, Writing &#x02013; Original Draft and Funding acquisition; RR was responsible for Writing &#x02013; Review &#x00026; Editing; AP was responsible for Writing &#x02013; Review &#x00026; Editing; JM was responsible for Resources, Writing &#x02013; Review &#x00026; Editing and Funding acquisition; JR was responsible for Resources, Validation, Writing &#x02013; Review &#x00026; Editing, Supervision and Funding acquisition.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by a Fellowships Research for Doctorate granted by the Foundation for Science and Technology (National Public Agency from Portugal) (FCT grant n.: 2021.07178.BD: 10.54499/2021.07178.BD). It was also supported from CIAFEL and ITR with installations and equipment (CIAFEL: UIDB/00617/2020: 10.54499/UIDB/00617/2020 and ITR: LA/P/0064/2020).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data is available online and described in references.</p></notes><notes><title>Declarations</title><notes id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par54">Ethic Commission Approval Centro Hospitalar de S&#x000e3;o Jo&#x000e3;o: CE 431-19.</p><p id="Par55">Ethic Commission Approval Faculty of Sport - University of Porto: CEFADE 14_2024</p></notes><notes id="FPar4"><title>Consent for publication</title><p id="Par56">Not applicable.</p></notes><notes id="FPar5" notes-type="COI-statement"><title>Competing Interests</title><p id="Par57">There is no competing interest of any authors of this review.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Swerdlow, S.H., et al., WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. 2017, Lyon: International Agency for Research on Cancer.</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Trends in disease burden of chronic lymphocytic leukemia at the global, regional, and national levels from 1990 to 2019, and projections until 2030: a population-based epidemiologic study</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>840616</fpage><pub-id pub-id-type="pmid">35359356</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Ou Y, et al. Trends in disease burden of chronic lymphocytic leukemia at the global, regional, and national levels from 1990 to 2019, and projections until 2030: a population-based epidemiologic study. Front Oncol. 2022;12: 840616.<pub-id pub-id-type="pmid">35359356</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Alaggio, R., et al., The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia, 2022. 36(7): p. 1720&#x02013;1748.</mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">NIH. SEER cancer stat facts: chronic lymphocytic leukemia. 2022 2023/01/12; Available from: <ext-link ext-link-type="uri" xlink:href="https://seer.cancer.gov/statfacts/html/clyl.html">https://seer.cancer.gov/statfacts/html/clyl.html</ext-link>. [cited 2023 2023/01/12].</mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019</article-title><source>Biomed Eng Online</source><year>2022</year><volume>21</volume><issue>1</issue><fpage>4</fpage><pub-id pub-id-type="pmid">35016695</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Yao Y, et al. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed Eng Online. 2022;21(1):4.<pub-id pub-id-type="pmid">35016695</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">LLS, The CLL guide: information for patients and caregivers. 2021, National Office: NY.</mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Swerdlow, S.H., et al., WHO classification of tumours of hematopoietic and lymphoid tissues. Revised 4th edition ed. 2017, Lyon: IARC Press.</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Hallek</surname><given-names>M</given-names></name></person-group><article-title>Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment</article-title><source>Am J Hematol</source><year>2019</year><volume>94</volume><issue>11</issue><fpage>1266</fpage><lpage>1287</lpage><pub-id pub-id-type="pmid">31364186</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94(11):1266&#x02013;87.<pub-id pub-id-type="pmid">31364186</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">International, C.L.L.I.P.I.w.g., An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol, 2016. 17(6): p. 779&#x02013;790.</mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Molica</surname><given-names>S</given-names></name><etal/></person-group><article-title>The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: independent validation in a prospective cohort of early stage patients</article-title><source>Am J Hematol</source><year>2016</year><volume>91</volume><issue>11</issue><fpage>1090</fpage><lpage>1095</lpage><pub-id pub-id-type="pmid">27465919</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Molica S, et al. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: independent validation in a prospective cohort of early stage patients. Am J Hematol. 2016;91(11):1090&#x02013;5.<pub-id pub-id-type="pmid">27465919</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>da Cunha-Bang</surname><given-names>C</given-names></name><name><surname>Christiansen</surname><given-names>I</given-names></name><name><surname>Niemann</surname><given-names>CU</given-names></name></person-group><article-title>The CLL-IPI applied in a population-based cohort</article-title><source>Blood</source><year>2016</year><volume>128</volume><issue>17</issue><fpage>2181</fpage><lpage>2183</lpage><pub-id pub-id-type="pmid">27605511</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">da Cunha-Bang C, Christiansen I, Niemann CU. The CLL-IPI applied in a population-based cohort. Blood. 2016;128(17):2181&#x02013;3.<pub-id pub-id-type="pmid">27605511</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Gentile</surname><given-names>M</given-names></name><etal/></person-group><article-title>Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients</article-title><source>Blood</source><year>2016</year><volume>128</volume><issue>16</issue><fpage>2093</fpage><lpage>2095</lpage><pub-id pub-id-type="pmid">27549308</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Gentile M, et al. Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood. 2016;128(16):2093&#x02013;5.<pub-id pub-id-type="pmid">27549308</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Kikushige</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia</article-title><source>Cancer Cell</source><year>2011</year><volume>20</volume><issue>2</issue><fpage>246</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">21840488</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Kikushige Y, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell. 2011;20(2):246&#x02013;59.<pub-id pub-id-type="pmid">21840488</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Kikushige</surname><given-names>Y</given-names></name></person-group><article-title>Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies</article-title><source>J Clin Exp Hematop</source><year>2020</year><volume>60</volume><issue>4</issue><fpage>146</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">33148933</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Kikushige Y. Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies. J Clin Exp Hematop. 2020;60(4):146&#x02013;58.<pub-id pub-id-type="pmid">33148933</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>YL</given-names></name></person-group><article-title>Prognostic and predictive molecular biomarkers in chronic lymphocytic leukemia</article-title><source>J Mol Diagn</source><year>2020</year><volume>22</volume><issue>9</issue><fpage>1114</fpage><lpage>1125</lpage><pub-id pub-id-type="pmid">32615167</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Lee J, Wang YL. Prognostic and predictive molecular biomarkers in chronic lymphocytic leukemia. J Mol Diagn. 2020;22(9):1114&#x02013;25.<pub-id pub-id-type="pmid">32615167</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>JA</given-names></name><name><surname>Gribben</surname><given-names>JG</given-names></name></person-group><article-title>The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies</article-title><source>Semin Cancer Biol</source><year>2014</year><volume>24</volume><fpage>71</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">24018164</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol. 2014;24:71&#x02013;81.<pub-id pub-id-type="pmid">24018164</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Scott, D.W. and R.D. Gascoyne, The tumour microenvironment in B cell lymphomas. Nature Reviews Cancer, 2014.</mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsay</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer</article-title><source>Blood</source><year>2012</year><volume>120</volume><issue>7</issue><fpage>1412</fpage><lpage>1421</lpage><pub-id pub-id-type="pmid">22547582</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Ramsay AG, et al. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012;120(7):1412&#x02013;21.<pub-id pub-id-type="pmid">22547582</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Kruger, K., et al., Intensive resistance exercise induces lymphocyte apoptosis via cortisol and glucocorticoid receptor-dependent pathways. J Appl Physiol (1985), 2011. 110(5): p. 1226&#x02013;32.</mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Effects of resistance exercise on antioxidant enzyme activities and apoptosis-related protein expression of hippocampus in OLETF rats</article-title><source>Technol Health Care</source><year>2018</year><volume>26</volume><issue>3</issue><fpage>457</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">29614709</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Lee MK, et al. Effects of resistance exercise on antioxidant enzyme activities and apoptosis-related protein expression of hippocampus in OLETF rats. Technol Health Care. 2018;26(3):457&#x02013;67.<pub-id pub-id-type="pmid">29614709</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Kruger</surname><given-names>K</given-names></name><etal/></person-group><article-title>Apoptosis of T-cell subsets after acute high-intensity interval exercise</article-title><source>Med Sci Sports Exerc</source><year>2016</year><volume>48</volume><issue>10</issue><fpage>2021</fpage><lpage>2029</lpage><pub-id pub-id-type="pmid">27183117</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Kruger K, et al. Apoptosis of T-cell subsets after acute high-intensity interval exercise. Med Sci Sports Exerc. 2016;48(10):2021&#x02013;9.<pub-id pub-id-type="pmid">27183117</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Goh</surname><given-names>J</given-names></name><name><surname>Niksirat</surname><given-names>N</given-names></name><name><surname>Campbell</surname><given-names>KL</given-names></name></person-group><article-title>Exercise training and immune crosstalk in breast cancer microenvironment: exploring the paradigms of exercise-induced immune modulation and exercise-induced myokines</article-title><source>Am J Transl Res</source><year>2014</year><volume>6</volume><issue>5</issue><fpage>422</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">25360210</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Goh J, Niksirat N, Campbell KL. Exercise training and immune crosstalk in breast cancer microenvironment: exploring the paradigms of exercise-induced immune modulation and exercise-induced myokines. Am J Transl Res. 2014;6(5):422&#x02013;38.<pub-id pub-id-type="pmid">25360210</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>P</given-names></name><name><surname>Chowdhury</surname><given-names>S</given-names></name><name><surname>Roy</surname><given-names>HK</given-names></name></person-group><article-title>Exercise-induced myokines as emerging therapeutic agents in colorectal cancer prevention and treatment</article-title><source>Future Oncol</source><year>2018</year><volume>14</volume><issue>4</issue><fpage>309</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">29318900</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Roy P, Chowdhury S, Roy HK. Exercise-induced myokines as emerging therapeutic agents in colorectal cancer prevention and treatment. Future Oncol. 2018;14(4):309&#x02013;12.<pub-id pub-id-type="pmid">29318900</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Barbalho</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Myokines: a descriptive review</article-title><source>J Sports Med Phys Fitness</source><year>2020</year><volume>60</volume><issue>12</issue><fpage>1583</fpage><lpage>1590</lpage><pub-id pub-id-type="pmid">32586076</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Barbalho SM, et al. Myokines: a descriptive review. J Sports Med Phys Fitness. 2020;60(12):1583&#x02013;90.<pub-id pub-id-type="pmid">32586076</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Exercise-induced myokines and their effect on prostate cancer</article-title><source>Nat Rev Urol</source><year>2021</year><volume>18</volume><issue>9</issue><fpage>519</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">34158658</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Kim JS, et al. Exercise-induced myokines and their effect on prostate cancer. Nat Rev Urol. 2021;18(9):519&#x02013;42.<pub-id pub-id-type="pmid">34158658</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Vasyukova</surname><given-names>OV</given-names></name><etal/></person-group><article-title>Myokines and adipomyokines: inflammatory mediators or unique molecules of targeted therapy for obesity?</article-title><source>Probl Endokrinol (Mosk)</source><year>2021</year><volume>67</volume><issue>4</issue><fpage>36</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">34533012</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Vasyukova OV, et al. Myokines and adipomyokines: inflammatory mediators or unique molecules of targeted therapy for obesity? Probl Endokrinol (Mosk). 2021;67(4):36&#x02013;45.<pub-id pub-id-type="pmid">34533012</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Kotani</surname><given-names>T</given-names></name><etal/></person-group><article-title>Influence of physical exercise on large granular lymphocytes, Leu-7 bearing mononuclear cells and natural killer activity in peripheral blood&#x02013;NK-cell and NK-activity after physical exercise</article-title><source>Nihon Ketsueki Gakkai Zasshi</source><year>1987</year><volume>50</volume><issue>6</issue><fpage>1210</fpage><lpage>1216</lpage><pub-id pub-id-type="pmid">3500563</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Kotani T, et al. Influence of physical exercise on large granular lymphocytes, Leu-7 bearing mononuclear cells and natural killer activity in peripheral blood&#x02013;NK-cell and NK-activity after physical exercise. Nihon Ketsueki Gakkai Zasshi. 1987;50(6):1210&#x02013;6.<pub-id pub-id-type="pmid">3500563</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Radom-Aizik, S., et al., Impact of brief exercise on peripheral blood NK cell gene and microRNA expression in young adults. J Appl Physiol (1985), 2013. 114(5): p. 628&#x02013;36.</mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Shek</surname><given-names>PN</given-names></name><etal/></person-group><article-title>Strenuous exercise and immunological changes: a multiple-time-point analysis of leukocyte subsets, CD4/CD8 ratio, immunoglobulin production and NK cell response</article-title><source>Int J Sports Med</source><year>1995</year><volume>16</volume><issue>7</issue><fpage>466</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">8550256</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Shek PN, et al. Strenuous exercise and immunological changes: a multiple-time-point analysis of leukocyte subsets, CD4/CD8 ratio, immunoglobulin production and NK cell response. Int J Sports Med. 1995;16(7):466&#x02013;74.<pub-id pub-id-type="pmid">8550256</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>HB</given-names></name><etal/></person-group><article-title>Lymphocytes and NK cell activity during repeated bouts of maximal exercise</article-title><source>Am J Physiol</source><year>1996</year><volume>271</volume><issue>1 Pt 2</issue><fpage>R222</fpage><lpage>R227</lpage><pub-id pub-id-type="pmid">8760224</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Nielsen HB, et al. Lymphocytes and NK cell activity during repeated bouts of maximal exercise. Am J Physiol. 1996;271(1 Pt 2):R222&#x02013;7.<pub-id pub-id-type="pmid">8760224</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Rumpf</surname><given-names>C</given-names></name><etal/></person-group><article-title>The effect of acute physical exercise on NK-cell cytolytic activity: a systematic review and meta-analysis</article-title><source>Sports Med</source><year>2021</year><volume>51</volume><issue>3</issue><fpage>519</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">33398798</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Rumpf C, et al. The effect of acute physical exercise on NK-cell cytolytic activity: a systematic review and meta-analysis. Sports Med. 2021;51(3):519&#x02013;30.<pub-id pub-id-type="pmid">33398798</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Crane</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Relationships between T-lymphocytes and physical function in adults with chronic lymphocytic leukemia: results from the HEALTH4CLL pilot study</article-title><source>Eur J Haematol</source><year>2023</year><volume>110</volume><issue>6</issue><fpage>732</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">36946440</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Crane JC, et al. Relationships between T-lymphocytes and physical function in adults with chronic lymphocytic leukemia: results from the HEALTH4CLL pilot study. Eur J Haematol. 2023;110(6):732&#x02013;42.<pub-id pub-id-type="pmid">36946440</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>G</given-names></name><etal/></person-group><article-title>A pilot study of high-intensity interval training in older adults with treatment naive chronic lymphocytic leukemia</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>23137</fpage><pub-id pub-id-type="pmid">34848750</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">MacDonald G, et al. A pilot study of high-intensity interval training in older adults with treatment naive chronic lymphocytic leukemia. Sci Rep. 2021;11(1):23137.<pub-id pub-id-type="pmid">34848750</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Higgins, J. and J. Thomas, Cochrane handbook for systematic reviews of interventions version 6, ed. J. Higgins and J. Thomas. 2019, Hoboken, NJ: Wiley Blackwell.</mixed-citation></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>MJ</given-names></name><name><surname>The</surname><given-names>PRISMA</given-names></name><etal/></person-group><article-title>statement: an updated guideline for reporting systematic reviews</article-title><source>Bmj-British Medical Journal</source><year>2020</year><volume>2021</volume><fpage>372</fpage></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Page MJ, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. Bmj-British Medical Journal. 2020;2021:372.</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>CONSORT,</surname></name><etal/></person-group><article-title>statement: updated guidelines for reporting parallel group randomised trials</article-title><source>Bmj-British Medical Journal</source><year>2010</year><volume>2010</volume><fpage>340</fpage></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Schulz KF, CONSORT, et al. statement: updated guidelines for reporting parallel group randomised trials. Bmj-British Medical Journal. 2010;2010:340.</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Vandenbroucke</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration</article-title><source>Int J Surg</source><year>2014</year><volume>12</volume><issue>12</issue><fpage>1500</fpage><lpage>1524</lpage><pub-id pub-id-type="pmid">25046751</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Vandenbroucke JP, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg. 2014;12(12):1500&#x02013;24.<pub-id pub-id-type="pmid">25046751</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Mataratzis, P.S.R., E. Accioly, and P.d.C. Padilha, Micronutrients deficiency in children and adolescents with sickle cell anemia: a systematic review. Rev. Bras. Hematol. Hemoter., 2010. 32(3): p. 247&#x02013;256.</mixed-citation></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Sterne</surname><given-names>JA</given-names></name><etal/></person-group><article-title>ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions</article-title><source>BMJ</source><year>2016</year><volume>355</volume><fpage>i4919</fpage><pub-id pub-id-type="pmid">27733354</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Sterne JA, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919.<pub-id pub-id-type="pmid">27733354</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Flemyng</surname><given-names>E</given-names></name><etal/></person-group><article-title>Using risk of bias 2 to assess results from randomised controlled trials: guidance from Cochrane</article-title><source>Bmj Evidence-Based Medicine</source><year>2023</year><volume>28</volume><issue>4</issue><fpage>260</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">36693715</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Flemyng E, et al. Using risk of bias 2 to assess results from randomised controlled trials: guidance from Cochrane. Bmj Evidence-Based Medicine. 2023;28(4):260&#x02013;6.<pub-id pub-id-type="pmid">36693715</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Sica, A., et al., An anecdotal case report of chronic lymphatic leukemia with del(11q) Treated with ibrutinib: artificial nourishment and physical activity program. International Journal of Environmental Research and Public Health, 2020. 17(6).</mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Artese, A.L., et al., Effects of high-intensity interval training on health-related quality of life in chronic lymphocytic leukemia: a pilot study. J Geriatr Oncol, 2022.</mixed-citation></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Courneya</surname><given-names>KS</given-names></name><etal/></person-group><article-title>Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>27</issue><fpage>4605</fpage><lpage>4612</lpage><pub-id pub-id-type="pmid">19687337</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Courneya KS, et al. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol. 2009;27(27):4605&#x02013;12.<pub-id pub-id-type="pmid">19687337</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Furzer</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>A randomised controlled trial comparing the effects of a 12-week supervised exercise versus usual care on outcomes in haematological cancer patients</article-title><source>Support Care Cancer</source><year>2016</year><volume>24</volume><issue>4</issue><fpage>1697</fpage><lpage>1707</lpage><pub-id pub-id-type="pmid">26423617</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Furzer BJ, et al. A randomised controlled trial comparing the effects of a 12-week supervised exercise versus usual care on outcomes in haematological cancer patients. Support Care Cancer. 2016;24(4):1697&#x02013;707.<pub-id pub-id-type="pmid">26423617</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="other">Persoon, S., et al., Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study. Plos One, 2017. 12(7).</mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">ACSM, ACSM&#x02019;s guidelines for exercise testing and prescription. Tenth ed. 2018, Philadelphia, PA: Wolters Kluwer Health.</mixed-citation></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Zigmond</surname><given-names>AS</given-names></name><name><surname>Snaith</surname><given-names>RP</given-names></name></person-group><article-title>The hospital anxiety and depression scale</article-title><source>Acta Psychiatr Scand</source><year>1983</year><volume>67</volume><issue>6</issue><fpage>361</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">6880820</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361&#x02013;70.<pub-id pub-id-type="pmid">6880820</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>AL</given-names></name></person-group><article-title>The Schwartz Cancer Fatigue Scale: testing reliability and validity</article-title><source>Oncol Nurs Forum</source><year>1998</year><volume>25</volume><issue>4</issue><fpage>711</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">9599354</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Schwartz AL. The Schwartz Cancer Fatigue Scale: testing reliability and validity. Oncol Nurs Forum. 1998;25(4):711&#x02013;7.<pub-id pub-id-type="pmid">9599354</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">McHorney, C.A., et al., The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care, 1994. 32(1): p. 40&#x02013;66.</mixed-citation></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>TW</given-names></name><name><surname>Ingram</surname><given-names>RE</given-names></name><name><surname>Brehm</surname><given-names>SS</given-names></name></person-group><article-title>Social anxiety, anxious self-preoccupation, and recall of self-relevant information</article-title><source>J Pers Soc Psychol</source><year>1983</year><volume>44</volume><issue>6</issue><fpage>1276</fpage><lpage>1283</lpage><pub-id pub-id-type="pmid">6875805</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Smith TW, Ingram RE, Brehm SS. Social anxiety, anxious self-preoccupation, and recall of self-relevant information. J Pers Soc Psychol. 1983;44(6):1276&#x02013;83.<pub-id pub-id-type="pmid">6875805</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Kohout</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Two shorter forms of the CES-D (Center for Epidemiological Studies Depression) depression symptoms index</article-title><source>J Aging Health</source><year>1993</year><volume>5</volume><issue>2</issue><fpage>179</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">10125443</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Kohout FJ, et al. Two shorter forms of the CES-D (Center for Epidemiological Studies Depression) depression symptoms index. J Aging Health. 1993;5(2):179&#x02013;93.<pub-id pub-id-type="pmid">10125443</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Fordyce, M.W., A review of research on the happiness measures: a sixty second index of happiness and mental health., in Citation classics from social indicators research, A.C. Michalos, Editor. 2005, Springer: Dordrecht.</mixed-citation></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Aaronson</surname><given-names>NK</given-names></name><etal/></person-group><article-title>The European-organization-for-research-and-treatment-of-cancer Qlq-C30-a quality-of-life instrument for use in international clinical-trials in oncology</article-title><source>J Natl Cancer Inst</source><year>1993</year><volume>85</volume><issue>5</issue><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">8433390</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Aaronson NK, et al. The European-organization-for-research-and-treatment-of-cancer Qlq-C30-a quality-of-life instrument for use in international clinical-trials in oncology. J Natl Cancer Inst. 1993;85(5):365&#x02013;76.<pub-id pub-id-type="pmid">8433390</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Aoun</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Measuring symptom distress in palliative care: psychometric properties of the Symptom Assessment Scale (SAS)</article-title><source>J Palliat Med</source><year>2011</year><volume>14</volume><issue>3</issue><fpage>315</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">21254812</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Aoun SM, et al. Measuring symptom distress in palliative care: psychometric properties of the Symptom Assessment Scale (SAS). J Palliat Med. 2011;14(3):315&#x02013;21.<pub-id pub-id-type="pmid">21254812</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Finkelstein, F.O., et al., Measurement properties of the short form-36 (SF-36) and the functional assessment of cancer therapy-anemia (FACT-An) in patients with anemia associated with chronic kidney disease. Health and Quality of Life Outcomes, 2018. 16.</mixed-citation></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Cerhan</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Anthropometric characteristics, physical activity, and risk of non-Hodgkin&#x02019;s lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study</article-title><source>Am J Epidemiol</source><year>2002</year><volume>156</volume><issue>6</issue><fpage>527</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">12226000</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Cerhan JR, et al. Anthropometric characteristics, physical activity, and risk of non-Hodgkin&#x02019;s lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. Am J Epidemiol. 2002;156(6):527&#x02013;35.<pub-id pub-id-type="pmid">12226000</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Body size, recreational physical activity, and B-cell non-Hodgkin lymphoma risk among women in the California teachers study</article-title><source>Am J Epidemiol</source><year>2009</year><volume>170</volume><issue>10</issue><fpage>1231</fpage><lpage>1240</lpage><pub-id pub-id-type="pmid">19822569</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Lu Y, et al. Body size, recreational physical activity, and B-cell non-Hodgkin lymphoma risk among women in the California teachers study. Am J Epidemiol. 2009;170(10):1231&#x02013;40.<pub-id pub-id-type="pmid">19822569</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>RB</given-names></name><name><surname>Buckley</surname><given-names>SA</given-names></name><name><surname>White</surname><given-names>E</given-names></name></person-group><article-title>Regular recreational physical activity and risk of hematologic malignancies: results from the prospective VITamins And lifestyle (VITAL) study</article-title><source>Ann Oncol</source><year>2013</year><volume>24</volume><issue>5</issue><fpage>1370</fpage><lpage>1377</lpage><pub-id pub-id-type="pmid">23247659</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Walter RB, Buckley SA, White E. Regular recreational physical activity and risk of hematologic malignancies: results from the prospective VITamins And lifestyle (VITAL) study. Ann Oncol. 2013;24(5):1370&#x02013;7.<pub-id pub-id-type="pmid">23247659</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Backer</surname><given-names>ICD</given-names></name><etal/></person-group><article-title>Resistance training in cancer survivors: a systematic review</article-title><source>Int J Sports Med</source><year>2009</year><volume>30</volume><fpage>703</fpage><lpage>712</lpage><pub-id pub-id-type="pmid">19585401</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Backer ICD, et al. Resistance training in cancer survivors: a systematic review. Int J Sports Med. 2009;30:703&#x02013;12.<pub-id pub-id-type="pmid">19585401</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Parikh</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Should IGHV status and FISH testing be performed in all CLL patients at diagnosis?</article-title><source>A systematic review and meta-analysis Blood</source><year>2016</year><volume>127</volume><issue>14</issue><fpage>1752</fpage><lpage>1760</lpage><pub-id pub-id-type="pmid">26841802</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Parikh SA, et al. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis Blood. 2016;127(14):1752&#x02013;60.<pub-id pub-id-type="pmid">26841802</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Molica</surname><given-names>S</given-names></name><etal/></person-group><article-title>Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis</article-title><source>Blood</source><year>2018</year><volume>131</volume><issue>3</issue><fpage>365</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">29084773</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Molica S, et al. Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis. Blood. 2018;131(3):365&#x02013;8.<pub-id pub-id-type="pmid">29084773</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Grgic</surname><given-names>J</given-names></name><name><surname>Schoenfeld</surname><given-names>BJ</given-names></name><name><surname>Latella</surname><given-names>C</given-names></name></person-group><article-title>Resistance training frequency and skeletal muscle hypertrophy: a review of available evidence</article-title><source>J Sci Med Sport</source><year>2019</year><volume>22</volume><issue>3</issue><fpage>361</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">30236847</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Grgic J, Schoenfeld BJ, Latella C. Resistance training frequency and skeletal muscle hypertrophy: a review of available evidence. J Sci Med Sport. 2019;22(3):361&#x02013;70.<pub-id pub-id-type="pmid">30236847</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenfeld</surname><given-names>BJ</given-names></name><name><surname>Grgic</surname><given-names>J</given-names></name><name><surname>Krieger</surname><given-names>J</given-names></name></person-group><article-title>How many times per week should a muscle be trained to maximize muscle hypertrophy? A systematic review and meta-analysis of studies examining the effects of resistance training frequency</article-title><source>J Sports Sci</source><year>2019</year><volume>37</volume><issue>11</issue><fpage>1286</fpage><lpage>1295</lpage><pub-id pub-id-type="pmid">30558493</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Schoenfeld BJ, Grgic J, Krieger J. How many times per week should a muscle be trained to maximize muscle hypertrophy? A systematic review and meta-analysis of studies examining the effects of resistance training frequency. J Sports Sci. 2019;37(11):1286&#x02013;95.<pub-id pub-id-type="pmid">30558493</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenfeld</surname><given-names>BJ</given-names></name><name><surname>Ogborn</surname><given-names>D</given-names></name><name><surname>Krieger</surname><given-names>JW</given-names></name></person-group><article-title>Effects of resistance training frequency on measures of muscle hypertrophy: a systematic review and meta-analysis</article-title><source>Sports Med</source><year>2016</year><volume>46</volume><issue>11</issue><fpage>1689</fpage><lpage>1697</lpage><pub-id pub-id-type="pmid">27102172</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Schoenfeld BJ, Ogborn D, Krieger JW. Effects of resistance training frequency on measures of muscle hypertrophy: a systematic review and meta-analysis. Sports Med. 2016;46(11):1689&#x02013;97.<pub-id pub-id-type="pmid">27102172</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Stamatakis</surname><given-names>E</given-names></name><etal/></person-group><article-title>Does strength-promoting exercise confer unique health benefits? A pooled analysis of data on 11 population cohorts with all-cause, cancer, and cardiovascular mortality endpoints</article-title><source>Am J Epidemiol</source><year>2018</year><volume>187</volume><issue>5</issue><fpage>1102</fpage><lpage>1112</lpage><pub-id pub-id-type="pmid">29099919</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Stamatakis E, et al. Does strength-promoting exercise confer unique health benefits? A pooled analysis of data on 11 population cohorts with all-cause, cancer, and cardiovascular mortality endpoints. Am J Epidemiol. 2018;187(5):1102&#x02013;12.<pub-id pub-id-type="pmid">29099919</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable</article-title><source>Med Sci Sports Exerc</source><year>2019</year><volume>51</volume><issue>11</issue><fpage>2375</fpage><lpage>2390</lpage><pub-id pub-id-type="pmid">31626055</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Campbell KL, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019;51(11):2375&#x02013;90.<pub-id pub-id-type="pmid">31626055</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Elter</surname><given-names>T</given-names></name><etal/></person-group><article-title>Is physical exercise possible in patients with critical cytopenia undergoing intensive chemotherapy for acute leukaemia or aggressive lymphoma?</article-title><source>Int J Hematol</source><year>2009</year><volume>90</volume><issue>2</issue><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">19629631</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Elter T, et al. Is physical exercise possible in patients with critical cytopenia undergoing intensive chemotherapy for acute leukaemia or aggressive lymphoma? Int J Hematol. 2009;90(2):199&#x02013;204.<pub-id pub-id-type="pmid">19629631</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Casado</surname><given-names>A</given-names></name><etal/></person-group><article-title>Exercise and the hallmarks of cancer</article-title><source>Trends Cancer</source><year>2017</year><volume>3</volume><issue>6</issue><fpage>423</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">28718417</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Ruiz-Casado A, et al. Exercise and the hallmarks of cancer. Trends Cancer. 2017;3(6):423&#x02013;41.<pub-id pub-id-type="pmid">28718417</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>